Perma-Fix Reports Third Quarter 2026 Results, with Sequential Growth of 39% in Revenue and 25% in Treatment Backlog from Second Quarter 2026

Treatment backlog of $19.6 million, up approximately 65% from year-end 2025

Perma-Fix Northwest now receiving both liquid effluent and dry waste from the Direct-Feed Low-Activity Waste (DFLAW) facility

Services Segment revenue up 46% year over year,

with gross margin improving to 12.2% from 6.7% and positive segment operating income

ATLANTA, Nov. 05, 2026 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the third quarter ended September 30, 2026.

Mark Duff, President and Chief Executive Officer of Perma-Fix, commented, “Our third quarter results reflect meaningful improvement over the first half of the year. Revenue increased 39% sequentially from second quarter of 2026, consolidated gross profit returned to positive territory and our net loss decreased from the second quarter. Results were held back by customer-directed changes in treatment protocols on a Hanford-related waste stream, which required performance testing and final approvals that were not provided until late August. Processing did not reach full operations until September, pushing revenue out of the quarter. We also took temporary downtime during the quarter to upgrade the thermal treatment systems at our Florida and Kingston facilities. Those upgrades were completed in September and are now supporting the large backlog of waste receipts we built over the summer. Treatment backlog grew approximately 25% during the quarter to $19.6 million, and the price increases we began implementing in August are also starting to be reflected in new backlog.

“At Hanford, Perma-Fix Northwest continues to receive liquid effluent from the U.S. Department of Energy’s (DOE) DFLAW facility and has begun receiving DFLAW dry waste, and we expect both to increase as DFLAW ramps up to higher production levels. DOE’s 2023 amended Record of Decision identified Perma-Fix Northwest to treat effluent waste from DFLAW operations, on an interim basis expected to last approximately 10 years. Beyond DFLAW, the Company is one of three contractors awarded a Master Indefinite Delivery/Indefinite Quantity (IDIQ) Subcontract by Hanford Tank Waste Operations & Closure, LLC (“H2C”), DOE’s prime contractor for tank waste operations and closure at the Hanford Site, for the treatment of certain Hanford waste streams. The Master IDIQ contemplates potential treatment of up to approximately 50 million gallons of waste through 2041, with an aggregate procurement ceiling of approximately $4.4 billion. These amounts represent overall procurement ceilings shared among the three IDIQ contract holders and do not represent amounts awarded or committed to the Company. The Company will compete for individual task orders issued under the Master IDIQ, and, while there can be no assurance as to the number, size or timing of task orders that may be awarded to the Company, we believe that our investments have positioned us to support increasing Hanford-related activity and to compete for task orders under DOE’s tank waste program. We are advancing facility upgrades to expand our grouting capacity to support that work. Among the three Master IDIQ Subcontract holders, we are the only one with a facility located adjacent to the Hanford Site, and waste treated under the subcontract would leave Perma-Fix Northwest as a stabilized, grouted solid shipped out of state by rail.

“Our Services Segment continued to grow, with revenue up 46% year over year, gross margin improving to 12.2% and the segment generating operating income. Our PFAS (Per- and polyfluoroalkyl) destruction business saw increased sales and receipts compared with the first half of the year. Our Gen 2.0 PFAS destruction unit is expected to begin commissioning in the fourth quarter of 2026, with operations anticipated to commence during the first half of 2027. The State of Florida enacted legislation this year phasing out PFAS-containing firefighting foam, subject to specified exceptions, which we expect to support continued demand for PFAS destruction. With a growing backlog, new pricing taking effect and DFLAW volumes increasing, we believe Perma-Fix is positioned for improved results in the coming year.”

Financial Results

Revenue for the third quarter of 2026 was approximately $17.9 million, compared to $17.5 million for the same period in 2025. The increase was attributable entirely to higher revenue within the Services Segment, which increased to approximately $6.3 million for the three months ended September 30, 2026, from approximately $4.4 million for the corresponding period of 2025, primarily due to increased project activity, including projects awarded since the beginning of 2026. Revenue within the Treatment Segment decreased to approximately $11.6 million for the three months ended September 30, 2026, from $13.1 million for the corresponding period of 2025. The decrease was primarily attributable to lower waste volumes processed, due in part to customer-directed changes in treatment protocols that delayed until September 2026 the processing of shipments of a certain Hanford-related waste stream received beginning in the second quarter of 2026 under the DOE Hanford program.

Gross profit for the third quarter of 2026 was $552,000 versus gross profit of $2.6 million for the third quarter of 2025. Services Segment gross profit increased by approximately $486,000, and gross margin improved to 12.2% from 6.7% in the prior-year period, primarily due to higher revenue and a more favorable mix of projects performed. Treatment Segment had a gross loss of $225,000 for the quarter ended September 30, 2026, as compared to a gross profit of approximately $2.3 million for the same period of 2025. The decline in gross profit of approximately $2.5 million and in gross margin to (1.9%) from 17.3% was primarily due to lower revenue resulting from reduced waste volumes and higher fixed operating costs, which were spread over a lower revenue base, further adversely impacting gross margin.

Loss from operations was approximately $3.7 million for the third quarter of 2026 versus loss from operations of $1.9 million for the third quarter of 2025. Net loss for the third quarter of 2026 was approximately $3.5 million or ($0.16) per basic share as compared to net loss of approximately $1.8 million or ($0.10) per basic share for the third quarter of 2025.

Our Quarterly Report on Form 10-Q for the period ended September 30, 2026 discloses that our recurring operating losses and negative operating cash flows continue to raise substantial doubt about our ability to continue as a going concern. Although our May 2026 public equity offering strengthened our liquidity position, continued operating losses since the offering and significant capital expenditures made during 2026 have reduced our liquidity. At September 30, 2026, we had approximately $19.9 million of PNC Liquidity, which consisted of approximately $5.5 million of borrowing availability under our revolving credit facility and approximately $14.3 million in cash held in our money market deposit account with our lender. In August 2026, we extended the maturity of our PNC credit facility from May 2027 to May 2030, among other amendments. We expect to fund our operations during the assessment period with our existing liquidity, anticipated operating cash flows, and borrowing availability. However, management concluded that substantial doubt has not been alleviated because the successful execution of our plans depends, in part, on the timing and volume of government-directed waste shipments and project activity, which remain subject to factors outside our control.

The Company reported EBITDA of ($3.1) million from continuing operations for the quarter ended September 30, 2026, as compared to EBITDA of ($1.5) million from continuing operations for the same period of 2025. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. EBITDA is not a measure of performance calculated in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”), and should not be considered in isolation of, or as a substitute for, earnings as an indicator of operating performance or cash flows from operating activities as a measure of liquidity. The Company believes the presentation of EBITDA is relevant and useful by enhancing the readers’ ability to understand the Company’s operating performance. The Company’s management utilizes EBITDA as a means to measure performance. The Company’s measurement of EBITDA may not be comparable to similar titled measures reported by other companies. The table below reconciles EBITDA, a non-GAAP measure, to GAAP numbers for loss from continuing operations for the three and nine months ended September 30, 2026, and 2025.

  Three Months Ended   Nine Months Ended  
  September 30,   September 30,  
(In thousands)   2026       2025       2026       2025    
Loss from continuing operations $ (3,408 )     $ (1,762 )     $ (17,046 )     $ (7,844 )    
                 
                 
Adjustments:                
Depreciation & amortization   495       426       1,469       1,299    
Interest income   (240 )     (266 )     (624 )     (901 )  
Interest expense   80       116       213       351    
Interest expense – financing fees   16       22       59       63    
Income tax expense   —       —       —       —    
                 
EBITDA $ (3,057 )   $ (1,464 )   $ (15,929 )   $ (7,032 )  
                 

The tables below present certain financial information for the business segments, which excludes allocation of corporate expenses.

    Three Months Ended   Nine Months Ended
    September 30, 2026   September 30, 2026
(In thousands)   Treatment   Services     Treatment   Services  
Net revenues   $ 11,601     $ 6,347     $ 27,768     $ 14,191    
Gross (loss) profit     (225 )     777       (5,711 )     878    
(Loss) income from operations     (1,722 )     201       (10,351 )     (927 )  
                     

    Three Months Ended   Nine Months Ended
    September 30, 2025   September 30, 2025
(In thousands)   Treatment   Services     Treatment   Services  
Net revenues   $ 13,114   $ 4,340       $ 33,696     $ 12,263    
Gross profit     2,266     291         4,082       679    
Income (loss) from operations     672     (457 )       (740 )     (1,650 )  
                     

Conference Call

Perma-Fix will host a conference call at 10:00 a.m. ET on Thursday, November 5, 2026. The call will be available on the Company’s website at https://ir.perma-fix.com/conference-calls, or by calling 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers, and by entering access code: 253188. The conference call will be led by Mark J. Duff, Chief Executive Officer, Dr. Louis F. Centofanti, Executive Vice President of Strategic Initiatives, and Ben Naccarato, Executive Vice President and Chief Financial Officer of Perma-Fix Environmental Services, Inc.

A webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, through Thursday, November 19, 2026, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code: 54752.

About Perma-Fix Environmental Services

Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company’s nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, U.S. Department of War (DOW), and the commercial nuclear industry. The Company’s nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, demolition, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOW, and commercial facilities nationwide.

Please visit us at http://www.perma-fix.com.

This press release contains “forward-looking statements” which are based largely on the Company’s expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company’s control. Forward-looking statements generally are identifiable by use of the words such as “believe”, “expects”, “intends”, “anticipate”, “plans to”, “estimates”, “projects”, and similar expressions. Forward-looking statements include, but are not limited to: improved results in the coming year; realization of Treatment Segment backlog; the timing and effect of pricing changes; processing of the Hanford-related waste stream delayed by customer-directed changes in treatment protocols; continued and increasing receipts of DFLAW-related liquid effluent and dry waste streams; the treatment of secondary waste at Perma-Fix Northwest under DOE’s 2023 amended Record of Decision and the duration of that arrangement; DOE’s 200 West Area tank waste program and our ability to compete for task orders under the Master IDIQ Subcontract; facility upgrades to expand our grouting capacity; the issuance, number, size and timing of task orders under the Master IDIQ Subcontract, if any; continued growth of the Services Segment; growth in PFAS sales and receipts; the effect of state legislation phasing out PFAS-containing firefighting foam on demand for PFAS destruction; commissioning of the Gen 2.0 PFAS destruction unit; and ability to continue to operate as a going concern. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; industry conditions; competitive pressures; our ability to apply and market our new technologies; acceptance of our PFAS destruction technology by the public; the government or such other party to a contract granted to us fails to abide by or comply with the contract or to deliver waste as anticipated under the contract or terminates existing contracts; Congress fails to provide funding for the DOW’s and DOE’s remediation projects; inability to obtain new foreign and domestic remediation contracts; the failure of H2C or DOE to issue task orders to the Company under the Master IDIQ Subcontract, or to issue them in the quantities or on the timing anticipated; competition from the other holders of Master IDIQ Subcontracts under the same procurement; the fact that identification of our facility in DOE planning or public materials does not constitute a contract, an award, or a commitment of any waste volumes; inability to be awarded any portion of DOE’s East Side or West Side tank waste grouting programs; failure or delay in obtaining approval from the Washington State Department of Ecology to expand our grouting permit capacity; delays or increased costs in completing the facility upgrades required to achieve expanded capacity; the fact that DOE’s proposed permit modifications remain subject to regulatory approval; opposition from state or regional regulators, governmental bodies, tribes or other stakeholders to the grouting or offsite transport and disposal of Hanford tank waste; litigation or administrative challenges to DOE’s tank waste treatment approach; changes in DOE’s treatment strategy, priorities or plans, or in the volumes, timing, composition or pricing of waste actually shipped to our facilities; and the additional factors referred to under “Risk Factors” and “Special Note Regarding Forward-Looking Statements” of our 2025 Form 10-K and Form 10-Qs for quarters ended March 31, 2026, June 30, 2026 and September 30, 2026. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

FINANCIAL TABLES FOLLOW

Contacts:

David K. Waldman-US Investor Relations
Crescendo Communications, LLC
(212) 671-1020
Herbert Strauss-European Investor Relations
[email protected]
+43 316 296 316

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
           
    Three Months Ended     Nine Months Ended
    September 30,     September 30,
(Amounts in Thousands, Except for Per Share Amounts)   2026       2025       2026       2025  
                       
Net revenues $ 17,948     $ 17,454     $ 41,959     $ 45,959  
Cost of goods sold   17,396       14,897       46,792       41,198  
Gross profit (loss)   552       2,557       (4,833 )     4,761  
                       
Selling, general and administrative expenses   3,998       4,083       12,047       12,228  
Research and development   225       342       781       1,037  
(Gain) loss on disposal of property and equipment   (5 )     4       (5 )     (2 )
Loss from operations   (3,666 )     (1,872 )     (17,656 )     (8,502 )
                       
Other income (expense):                      
Interest income   240       266       624       901  
Interest expense   (80 )     (116 )     (213 )     (351 )
Interest expense-financing fees   (16 )     (22 )     (59 )     (63 )
Other   114       (18 )     258       171  
Loss from continuing operations before taxes   (3,408 )     (1,762 )     (17,046 )     (7,844 )
Income tax expense   —       —       —       —  
Loss from continuing operations, net of taxes   (3,408 )     (1,762 )     (17,046 )     (7,844 )
                       
Loss from discontinued operations, net of taxes   (54 )     (73 )     (103 )     (280 )
Net loss $ (3,462 )   $ (1,835 )   $ (17,149 )   $ (8,124 )
                       
Net loss per common share – basic and diluted:                      
Continuing operations $ (.16)   $ (.10)   $ (.86)   $ (.43)
Discontinued operations   —       —       (.01)     (.02)
Net loss per common share $ (.16)   $ (.10)   $ (.86)   $ (.44)
                       
                       
Weighted average number of common shares used in computing                  
net loss per share:                      
Basic   21,218       18,472       19,877       18,448  
Diluted   21,218       18,472       19,877       18,448  

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

CONDENSED CONSOLIDATED BALANCE SHEET
       
    September 30, December 31,
(Amounts in Thousands, Except for Share and Per Share Amounts)     2026       2025  
         
ASSETS        
Current assets:        
Cash   $ 14,743     $ 11,768  
Account receivable, net of allowance for credit losses of $55 and        
$309, respectively     10,278       11,228  
Unbilled receivables     11,898       8,781  
Other current assets     6,881       4,534  
Assets of discontinued operations included in current assets     105       60  
Total current assets     43,905       36,371  
         
Net property and equipment     30,336       24,600  
Property and equipment of discontinued operations     146       146  
Operating lease right-of-use assets     1,183       1,445  
Intangibles and other assets     26,871       25,472  
Total assets   $ 102,441     $ 88,034  
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities   $ 31,227     $ 22,298  
Current liabilities related to discontinued operations     1,284       270  
Total current liabilities     32,511       22,568  
         
Long-term liabilities     12,233       11,729  
Long-term liabilities related to discontinued operations     2,472       3,598  
Total liabilities     47,216       37,895  
Commitments and Contingencies        
Stockholders’ equity:        
Preferred Stock, $.001 par value; 2,000,000 shares authorized,        
no shares issued and outstanding     —       —  
Common Stock, $.001 par value; 30,000,000 shares authorized,        
21,226,930 and 18,525,823 shares issued, respectively;        
21,219,288 and 18,518,181 shares outstanding, respectively     21       18  
Additional paid-in capital     183,320       161,057  
Accumulated deficit     (127,863 )     (110,714 )
Accumulated other comprehensive loss     (165 )     (134 )
Less Common Stock held in treasury, at cost: 7,642 shares     (88 )     (88 )
Total stockholders’ equity     55,225       50,139  
         
Total liabilities and stockholders’ equity   $ 102,441     $ 88,034  



LCI Industries Reports Third Quarter Financial Results

LCI Industries Reports Third Quarter Financial Results

Growth in Adjacent Industries and Aftermarket; Strong Execution Drives Operating Margin Expansion

Third Quarter 2026 Highlights versus Third Quarter 2025

  • Consolidated net sales of $992 million relative to $1,036 million

  • Diversified businesses grew, with Adjacent Industries net sales growth of 7% and Aftermarket up 6%, partially mitigating lower RV OEM sales

  • Operating profit margin expanded 30 bps to 7.6% from 7.3%

  • Adjusted operating profit margin, which excludes the impacts of merger-related expenses and restructuring costs, expanded 100 bps to 8.3% from 7.3%

  • Net income of $50 million, or 5.0% of net sales, relative to $62 million, or 6.0% of net sales

  • Diluted earnings per share decreased 20% to $2.05 relative to $2.55

  • Adjusted net income of $54 million; adjusted diluted EPS increased 12% to $2.21 from $1.97

  • Adjusted EBITDA of $111 million, or 11.2% of net sales, up from $106 million, or 10.2% of net sales

  • Towable RV content per unit up 6% to $5,733

Other Highlights

  • Cash flows from operations of $316 million for the LTM ended September 30, 2026

  • $28 million returned to shareholders via dividends during the quarter

  • Strong liquidity position of $841 million, comprising $246 million of cash and cash equivalents and $595 million of availability on revolving credit facility at September 30, 2026

  • As previously announced, on June 30, 2026, the Company entered into a definitive agreement to combine with Patrick Industries, Inc. in an all-stock merger. The Company will hold a special meeting of stockholders on November 18, 2026. Please visit www.PatrickandLippertTogether.com for more information.

ELKHART, Ind.–(BUSINESS WIRE)–
LCI Industries (NYSE: LCII), a leading supplier of engineered components to the recreation and transportation markets, today reported third quarter 2026 results.

“Our third-quarter results reflect continued progress in improving profitability in a soft outdoor recreation market. Margin expansion and 6% growth in product content per unit contributed to our performance and position us to achieve our updated full-year outlook,” said Johnny Sirpilla, Interim Chief Executive Officer. “Our 2026 performance has been driven by taking actions on those areas within our control. This includes the ongoing pursuit of operational efficiencies and strategic cost reductions. Our cost management and growth in adjacent industries and aftermarket sales contributed to our bottom line results and we believe leave us well-positioned as conditions normalize.”

Mr. Sirpilla continued, “Our new product pipeline and the repair and replacement needs of the installed RV base provide opportunities to serve customers even as demand for new units remains constrained. We are also advancing toward the proposed merger with Patrick Industries, which we continue to expect to close in the first half of 2027. Until that time, our focus remains on disciplined execution and strengthening the business under current market conditions, while driving long-term shareholder value.”

Third Quarter 2026 Results

Consolidated net sales of $992.5 million in the third quarter of 2026 compares to $1,036.5 million in the same period of 2025. The decrease in consolidated net sales was primarily driven by lower North American RV wholesale shipments, partially offset by increases in selling prices contractually tied to indices of select commodities, growth in the automotive aftermarket, and sales from acquired businesses ($5.2 million in the third quarter).

Net income was $50.1 million, or $2.05 per diluted share, compared to $62.5 million, or $2.55 per diluted share, in the third quarter of 2025. Adjusted net income increased to $54.0 million, or $2.21 per diluted share, compared to $48.1 million, or $1.97 per diluted share. Adjusted EBITDA increased to $111.5 million, compared to $105.9 million in the third quarter of 2025. Operating profit margin increased to 7.6% in the third quarter of 2026 compared to 7.3% in the same period of 2025. Year-over-year margin expansion was driven primarily by cost improvement actions, including materials sourcing strategies, partially offset by lower absorption of fixed costs due to lower sales volumes and merger-related expenses.

*Additional information regarding adjusted net income, adjusted EPS, adjusted EBITDA, and adjusted operating profit margin used throughout this release, as well as reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measure, is provided in the “Supplementary Information – Reconciliation of Non-GAAP Measures” section below.

OEM Segment – Third Quarter Performance

OEM net sales decreased $57.7 million, or 7%, to $732.3 million for the third quarter of 2026, compared to $790.0 million in the same period of 2025. RV OEM net sales decreased 17% to $389.9 million, primarily due to a decrease in North American travel trailer and fifth-wheel shipments, and a change in RV sales mix toward more lower content single axle travel trailers, partially offset by increases in selling prices contractually tied to indices of select commodities. Adjacent Industries OEM net sales increased 7% year-over-year to $342.4 million, primarily driven by higher sales to North American transportation, marine, and manufactured housing OEMs.

Operating profit of the OEM Segment was $44.1 million in the third quarter of 2026, or 6.0% of net sales, compared to $43.6 million, or 5.5% of net sales, in the same period in 2025. Operating profit margin of the OEM Segment benefited primarily from increases in selling prices contractually tied to indices of select commodities, cost improvement actions, including materials sourcing strategies, and a favorable shift in component sales mix, partially offset by the impact of fixed costs spread over decreased production volumes, decreases in selling prices for certain products primarily related to changes in tariff costs, higher material and freight costs, including higher steel and aluminum costs and rising fuel costs, as well as merger-related expenses.

Aftermarket Segment – Third Quarter Performance

Aftermarket net sales increased 6% to $260.2 million for the third quarter of 2026, compared to $246.5 million in the same period of 2025. The increase was primarily driven by increases in volume in the automotive aftermarket.

Operating profit of the Aftermarket Segment was $30.9 million, or 11.9% of net sales in the third quarter of 2026, compared to $31.9 million, or 12.9% of net sales, in the same period of 2025. Operating profit margin of the Aftermarket Segment was negatively impacted by higher material and freight costs related to tariffs, higher steel and aluminum costs, rising fuel costs, investments in capacity and distribution to support the Aftermarket Segment, restructuring costs to support growth in the automotive aftermarket, and merger-related expenses, partially offset by the impact of fixed costs spread over increased automotive aftermarket production volumes, cost improvement actions, including materials sourcing strategies, and increases in selling prices for targeted products and to cover increased material costs.

Income Taxes

The Company’s effective tax rate was 26.7% for the quarter ended September 30, 2026, compared to 25.6% for the quarter ended September 30, 2025. The increase in the effective tax rate was primarily due to the reduction in a discrete tax benefit related to an increase in the cash surrender value of company-owned life insurance policies compared to the prior year period and a write-off of projected non-deductible deferred executive compensation.

Balance Sheet and Other Items

At September 30, 2026, the Company’s cash and cash equivalents balance was $245.6 million, relative to $222.6 million at December 31, 2025. The Company used $92.0 million to pay off the remaining balance of its 2026 Convertible Notes at maturity, $83.8 million for dividend payments to shareholders, and $41.9 million for capital expenditures in the nine months ended September 30, 2026.

The Company’s outstanding long-term indebtedness, including current maturities, was $852.4 million at September 30, 2026. As of September 30, 2026, the Company had $595.4 million of borrowing availability under its revolving credit facility.

Outlook

Based on current market and economic conditions along with existing tariffs, the Company currently expects the following:

  • October 2026 net sales of approximately $341 million, down 10% from prior year

  • 2026 North American RV wholesale shipments of 285,000 to 295,000

  • 2026 revenue of $3.9 billion to $4.0 billion

  • 2026 adjusted operating profit margin of 7.5% to 8.0%

  • 2026 adjusted EPS of $8.25 to $8.50

Conference Call & Webcast

LCI Industries will host a conference call to discuss its third quarter results on Thursday, November 5, 2026, at 8:30 a.m. Eastern time. An online, real-time webcast, as well as a supplemental earnings presentation, will be available on the Company’s website, investors.lci1.com. The conference call and webcast can also be accessed by dialing (833) 461-5787 for participants in the U.S. and (585) 542-9983 for participants outside the U.S. using the required access code 567748958#. Due to the high volume of companies reporting earnings at this time, please be prepared for hold times of up to 15 minutes when dialing in to the call.

A replay of the conference call will be available for two weeks by dialing (833) 309-1852 for participants in the U.S. and (929) 828-5978 for those outside the U.S. and referencing access code 567748958#. A replay of the webcast will be available on the Company’s website immediately following the conclusion of the call.

About LCI Industries

LCI Industries (NYSE: LCII), through its Lippert subsidiary, is a global leader in supplying engineered components to the outdoor recreation and transportation markets. We believe our innovative culture, advanced manufacturing capabilities, and dedication to enhancing the customer experience have established Lippert as a reliable partner for both OEM and aftermarket customers. For more information, visit www.lippert.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” with respect to our financial condition, results of operations, profitability, margins, business strategies, operating efficiencies or synergies, competitive position, growth opportunities, acquisitions, plans and objectives of management, markets for the Company’s common stock, the impact of legal proceedings, and other matters. Statements in this press release that are not historical facts are “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and involve a number of risks and uncertainties.

Forward-looking statements, including, without limitation, those relating to the Company’s 2026 outlook and related assumptions, production levels, future financial results and business prospects, net sales, expenses and income (loss), operating margins, capital expenditures, tax rate, cash flow, financial condition, liquidity, covenant compliance, retail and wholesale demand and shipments, run rates, integration of acquisitions, planned divestitures and facility consolidations, optimization of facilities and infrastructure, R&D investments, commodity prices, addressable markets, industry trends, and the Company’s proposed merger with Patrick Industries, Inc. (“Patrick”), whenever they occur in this press release are necessarily estimates reflecting the best judgment of the Company’s senior management at the time such statements were made. There are a number of factors, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those described in the forward-looking statements. These factors include, in addition to other matters described in this press release, (1) the impacts of costs and availability of, and tariffs on, raw materials (particularly steel and aluminum) and other components, (2) tariff refunds and related pass through to customers, (3) future pandemics, geopolitical tensions, armed conflicts, or natural disasters on the global economy and on the Company’s customers, suppliers, team members, business and cash flows, (4) pricing pressures due to domestic and foreign competition, (5) seasonality and cyclicality in the industries to which we sell our products, (6) availability of credit for financing the retail and wholesale purchase of products for which we sell our components, (7) inventory levels of retail dealers and manufacturers, availability of transportation for products for which we sell our components, (8) the financial condition of our customers, (9) the financial condition of retail dealers of products for which we sell our components, (10) retention and concentration of significant customers, (11) the costs, pace of and successful integration of acquisitions and other growth initiatives, (12) availability and costs of production facilities and labor, team member benefits, team member retention, realization and impact of expansion plans, (13) efficiency improvements and cost reductions, (14) the disruption of business resulting from natural disasters or other unforeseen events, (15) the successful entry into new markets, (16) the costs of compliance with environmental laws, laws of foreign jurisdictions in which we operate, other operational and financial risks related to conducting business internationally, and increased governmental regulation and oversight, (17) information technology performance and security, (18) the ability to protect intellectual property, (19) warranty and product liability claims or product recalls, (20) interest rates, oil and gasoline prices, and availability, the impact of international, national and regional economic conditions and consumer confidence on the retail sale of products for which we sell our components, (21) risks related to the pending merger with Patrick, including (a) the risk that the cost savings and any revenue synergies from the transaction may not be fully realized or may take longer than anticipated to be realized, (b) disruption to each party’s business as a result of the announcement and pendency of the transaction, (c) the risk that the integration of each party’s operations will be materially delayed or will be more costly or difficult than expected or that the parties are otherwise unable to successfully integrate as a result of unexpected factors or events, (d) the failure to obtain the necessary approvals by the stockholders of the Company or Patrick, (e) the ability by each of the Company and Patrick to obtain required governmental approvals of the transaction on the timeline expected, or at all, and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction, (f) reputational risk and the reaction of each party’s customers, suppliers, employees or other business partners to the transaction, (g) the failure of the closing conditions in the merger agreement to be satisfied, or any unexpected delay in closing the transaction or the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, (h) the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events, (i) risks related to management and oversight of the expanded business and operations of the combined company due to the increased size and complexity, (j) the possibility of increased scrutiny by, and/or additional regulatory requirements of, governmental authorities as a result of the transaction or the size, scope and complexity of the combined company’s business operations, and (k) the outcome of any legal or regulatory proceedings that may be currently pending or later instituted against the Company, Patrick or the combined company before or after the transaction, and (22) other risks and uncertainties discussed more fully under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 and in the Company’s subsequent filings with the Securities and Exchange Commission (the “SEC”). Readers of this press release are cautioned not to place undue reliance on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. The Company disclaims any obligation or undertaking to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made, except as required by law.

Important Information About the Proposed Transaction and Where to Find It

In connection with the proposed transaction between the Company and Patrick, Patrick has filed relevant materials with the SEC, including, among other filings, a Patrick registration statement on Form S-4 (File No. 333-299100) that includes a preliminary joint proxy statement of the Company and Patrick that also constitutes a prospectus of Patrick with respect to shares of Patrick’s common stock to be issued in the proposed transaction. The registration statement was declared effective by the SEC on October 19, 2026, and the Company and Patrick commenced mailing the definitive joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”) to their respective stockholders on or about October 19, 2026. The Company and Patrick may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the Joint Proxy Statement/Prospectus or any other document which the Company and Patrick may file with the SEC. INVESTORS AND SECURITY HOLDERS OF THE COMPANY AND PATRICK ARE URGED TO READ THE REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders are able to obtain free copies of the registration statement and the Joint Proxy Statement/Prospectus and other documents filed with the SEC by the Company and Patrick through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company are available free of charge on the Company’s website at lippert.com under the tab “Investors” and under the heading “Financials” and subheading “SEC Filings.” Copies of the documents filed with the SEC by Patrick are available free of charge on Patrick’s website at patrickind.com under the tab “Investors” and under the heading “SEC Filings.”

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

LCI INDUSTRIES

OPERATING RESULTS

(unaudited)

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

Last Twelve

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

 

Months

(In thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

992,483

 

 

$

1,036,477

 

 

$

3,051,675

 

 

$

3,189,317

 

 

$

3,984,375

 

Cost of sales

 

728,688

 

 

 

783,864

 

 

 

2,213,071

 

 

 

2,414,934

 

 

 

2,939,859

 

Gross profit

 

263,795

 

 

 

252,613

 

 

 

838,604

 

 

 

774,383

 

 

 

1,044,516

 

Warehouse and transportation

 

59,458

 

 

 

49,650

 

 

 

176,682

 

 

 

153,740

 

 

 

228,002

 

Selling, general and administrative expenses

 

129,322

 

 

 

127,524

 

 

 

395,788

 

 

 

376,083

 

 

 

515,018

 

Operating profit

 

75,015

 

 

 

75,439

 

 

 

266,134

 

 

 

244,560

 

 

 

301,496

 

Interest expense, net

 

8,389

 

 

 

10,323

 

 

 

24,621

 

 

 

26,003

 

 

 

34,328

 

Loss on extinguishment of debt

 

—

 

 

 

806

 

 

 

—

 

 

 

8,859

 

 

 

—

 

Gain on sale of real estate

 

(1,681

)

 

 

(19,716

)

 

 

(2,235

)

 

 

(19,716

)

 

 

(2,235

)

Income before income taxes

 

68,307

 

 

 

84,026

 

 

 

243,748

 

 

 

229,414

 

 

 

269,403

 

Provision for income taxes

 

18,220

 

 

 

21,533

 

 

 

63,573

 

 

 

59,848

 

 

 

70,544

 

Net income

$

50,087

 

 

$

62,493

 

 

$

180,175

 

 

$

169,566

 

 

$

198,859

 

 

 

 

 

 

 

 

 

 

 

Net income per common share:

 

 

 

 

 

 

 

 

 

Basic

$

2.06

 

 

$

2.56

 

 

$

7.42

 

 

$

6.79

 

 

$

8.19

 

Diluted

$

2.05

 

 

$

2.55

 

 

$

7.39

 

 

$

6.78

 

 

$

8.16

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

24,322

 

 

 

24,389

 

 

 

24,288

 

 

 

24,978

 

 

 

24,272

 

Diluted

 

24,417

 

 

 

24,466

 

 

 

24,376

 

 

 

25,004

 

 

 

24,371

 

 

 

 

 

 

 

 

 

 

 

Depreciation

$

15,999

 

 

$

16,706

 

 

$

50,019

 

 

$

50,195

 

 

$

66,878

 

Amortization

$

12,943

 

 

$

13,779

 

 

$

39,579

 

 

$

40,155

 

 

$

53,601

 

Capital expenditures

$

13,445

 

 

$

16,297

 

 

$

41,877

 

 

$

38,071

 

 

$

56,450

 

LCI INDUSTRIES

SEGMENT RESULTS

(unaudited)

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

Last Twelve

 

2026

 

2025

 

2026

 

2025

 

Months

(In thousands)

 

 

 

 

 

 

 

 

 

Net sales:

 

 

 

 

 

 

 

 

 

OEM Segment:

 

 

 

 

 

 

 

 

 

RV OEMs:

 

 

 

 

 

 

 

 

 

Travel trailers and fifth-wheels

$

337,852

 

$

412,472

 

$

1,062,207

 

$

1,325,592

 

$

1,444,851

Motorhomes

 

52,013

 

 

57,635

 

 

173,622

 

 

178,615

 

 

230,983

Adjacent Industries OEMs

 

342,420

 

 

319,916

 

 

1,024,063

 

 

948,930

 

 

1,320,574

Total OEM Segment net sales

 

732,285

 

 

790,023

 

 

2,259,892

 

 

2,453,137

 

 

2,996,408

Aftermarket Segment:

 

 

 

 

 

 

 

 

 

Total Aftermarket Segment net sales

 

260,198

 

 

246,454

 

 

791,783

 

 

736,180

 

 

987,967

Total net sales

$

992,483

 

$

1,036,477

 

$

3,051,675

 

$

3,189,317

 

$

3,984,375

 

 

 

 

 

 

 

 

 

 

Operating profit:

 

 

 

 

 

 

 

 

 

OEM Segment

$

44,117

 

$

43,570

 

$

164,704

 

$

157,227

 

$

191,597

Aftermarket Segment

 

30,898

 

 

31,869

 

 

101,430

 

 

87,333

 

 

109,899

Total operating profit

$

75,015

 

$

75,439

 

$

266,134

 

$

244,560

 

$

301,496

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization:

 

 

 

 

 

 

 

 

 

OEM Segment depreciation

$

10,184

 

$

11,992

 

$

33,749

 

$

36,488

 

$

45,592

Aftermarket Segment depreciation

 

5,815

 

 

4,714

 

 

16,270

 

 

13,707

 

 

21,286

Total depreciation

$

15,999

 

$

16,706

 

$

50,019

 

$

50,195

 

$

66,878

 

 

 

 

 

 

 

 

 

 

OEM Segment amortization

$

8,951

 

$

9,917

 

$

27,512

 

$

28,669

 

$

37,508

Aftermarket Segment amortization

 

3,992

 

 

3,862

 

 

12,067

 

 

11,486

 

 

16,093

Total amortization

$

12,943

 

$

13,779

 

$

39,579

 

$

40,155

 

$

53,601

LCI INDUSTRIES

BALANCE SHEET INFORMATION

(unaudited)

 

 

September 30,

2026

 

December 31,

2025

 

 

(In thousands)

 

 

 

ASSETS

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

245,618

 

$

222,615

Accounts receivable, net

 

385,231

 

 

243,425

Inventories, net

 

746,726

 

 

809,094

Prepaid expenses and other current assets

 

68,132

 

 

74,552

Total current assets

 

1,445,707

 

 

1,349,686

Fixed assets, net

 

405,705

 

 

428,031

Goodwill

 

618,906

 

 

622,183

Other intangible assets, net

 

359,782

 

 

402,568

Operating lease right-of-use assets

 

268,390

 

 

272,995

Other long-term assets

 

101,656

 

 

100,524

Total assets

$

3,200,146

 

$

3,175,987

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities

 

 

 

Current maturities of long-term indebtedness

$

3,650

 

$

3,683

Accounts payable, trade

 

196,353

 

 

202,257

Current portion of operating lease obligations

 

46,074

 

 

44,174

Accrued expenses and other current liabilities

 

266,778

 

 

223,253

Total current liabilities

 

512,855

 

 

473,367

Long-term indebtedness

 

848,745

 

 

941,502

Operating lease obligations

 

241,190

 

 

246,047

Deferred taxes

 

28,002

 

 

27,495

Other long-term liabilities

 

111,299

 

 

126,743

Total liabilities

 

1,742,091

 

 

1,815,154

Total stockholders’ equity

 

1,458,055

 

 

1,360,833

Total liabilities and stockholders’ equity

$

3,200,146

 

$

3,175,987

LCI INDUSTRIES

SUMMARY OF CASH FLOWS

(unaudited)

 

Nine Months Ended

September 30,

 

 

2026

 

 

 

2025

 

(In thousands)

 

 

 

Cash flows from operating activities:

 

 

 

Net income

$

180,175

 

 

$

169,566

 

Adjustments to reconcile net income to cash flows provided by operating activities:

 

 

 

Depreciation and amortization

 

89,598

 

 

 

90,350

 

Stock-based compensation expense

 

17,030

 

 

 

16,868

 

Loss on extinguishment of debt

 

—

 

 

 

8,859

 

Gain on sale of real estate

 

(2,235

)

 

 

(19,716

)

Other non-cash items

 

6,839

 

 

 

9,860

 

Changes in assets and liabilities, net of acquisitions of businesses:

 

 

 

Accounts receivable, net

 

(144,308

)

 

 

(145,752

)

Inventories, net

 

60,987

 

 

 

33,176

 

Prepaid expenses and other assets

 

1,567

 

 

 

11,069

 

Accounts payable, trade

 

(3,360

)

 

 

24,333

 

Accrued expenses and other liabilities

 

30,982

 

 

 

53,491

 

Net cash flows provided by operating activities

 

237,275

 

 

 

252,104

 

Cash flows from investing activities:

 

 

 

Capital expenditures

 

(41,877

)

 

 

(38,071

)

Acquisition of businesses

 

—

 

 

 

(102,990

)

Proceeds from sale of real estate

 

3,681

 

 

 

22,674

 

Other investing activities

 

7,701

 

 

 

(3,249

)

Net cash flows used in investing activities

 

(30,495

)

 

 

(121,636

)

Cash flows from financing activities:

 

 

 

Vesting of stock-based awards, net of shares tendered for payment of taxes

 

(6,718

)

 

 

(5,242

)

Repayments under revolving credit facility

 

—

 

 

 

(19,261

)

Proceeds from term loan borrowings

 

—

 

 

 

391,000

 

Repayments under term loan and other borrowings

 

(3,225

)

 

 

(282,535

)

Proceeds from issuance of convertible notes

 

—

 

 

 

448,500

 

Repurchase of convertible notes

 

(92,000

)

 

 

(368,920

)

Purchases of convertible note hedge contracts

 

—

 

 

 

(67,574

)

Proceeds from issuance of warrants concurrent with note hedge contracts

 

—

 

 

 

27,600

 

Payment of dividends

 

(83,838

)

 

 

(86,215

)

Repurchases of common stock

 

—

 

 

 

(128,571

)

Other financing activities

 

—

 

 

 

(4,998

)

Net cash flows used in financing activities

 

(185,781

)

 

 

(96,216

)

Effect of exchange rate changes on cash and cash equivalents

 

2,004

 

 

 

(287

)

Net increase in cash and cash equivalents

 

23,003

 

 

 

33,965

 

Cash and cash equivalents at beginning of period

 

222,615

 

 

 

165,756

 

Cash and cash equivalents at end of period

$

245,618

 

 

$

199,721

 

LCI INDUSTRIES

SUPPLEMENTARY INFORMATION

(unaudited)

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

Last Twelve

 

2026

 

2025

 

 

2026

 

 

 

2025

 

 

Months

Industry Data(1)(in thousands of units):

 

 

 

 

 

 

 

 

 

Industry Wholesale Production:

 

 

 

 

 

 

 

 

 

Travel trailer and fifth-wheel RVs

57.4

 

 

65.7

 

 

 

196.3

 

 

 

233.5

 

 

 

261.0

 

Motorhome RVs

7.7

 

 

8.9

 

 

 

28.2

 

 

 

27.6

 

 

 

36.6

 

Industry Retail Sales:

 

 

 

 

 

 

 

 

 

Travel trailer and fifth-wheel RVs

75.6

 

 

90.7

 

 

 

215.8

 

 

 

254.0

 

 

 

267.9

 

Impact on dealer inventories

(18.2

)

 

(25.0

)

 

 

(19.5

)

 

 

(20.5

)

 

 

(6.9

)

Motorhome RVs

9.6

 

 

10.4

 

 

 

27.6

 

 

 

30.1

 

 

 

35.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Twelve Months Ended

 

 

 

 

 

 

 

September 30,

 

 

 

 

 

 

 

 

2026

 

 

 

2025

 

 

 

Lippert Content Per Industry Unit Produced(2):

 

 

 

 

 

 

 

 

 

Travel trailer and fifth-wheel RV

 

 

 

 

$

5,733

 

 

$

5,431

 

 

 

Motorhome RV

 

 

 

 

$

3,873

 

 

$

3,839

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

 

 

 

 

2026

 

 

 

2025

 

 

 

2025

 

Balance Sheet Data (debt availability in millions):

 

 

 

 

 

 

 

 

 

Remaining availability under the revolving credit facility(3)

 

 

 

 

$

595.4

 

 

$

595.2

 

 

$

595.2

 

Days sales in accounts receivable, based on last twelve months

 

 

 

 

 

31.3

 

 

 

29.4

 

 

 

29.7

 

Inventory turns, based on last twelve months

 

 

 

 

 

3.7

 

 

 

4.2

 

 

 

4.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated Full Year Data:

 

 

 

 

2026

 

 

Revenue

 

 

 

 

$3.9 – $4.0 billion

 

 

Adjusted operating profit margin(4)

 

 

 

 

7.5% – 8.0%

 

 

Adjusted diluted EPS

 

 

 

 

$8.25 – $8.50

 

 

Capital expenditures

 

 

 

 

$55 – $65 million

 

 

Depreciation and amortization

 

 

 

 

$115 – $125 million

 

 

Stock-based compensation expense

 

 

 

 

$22 – $25 million

 

 

Annual tax rate

 

 

 

 

25% – 27%

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Industry wholesale production data for travel trailer and fifth-wheel RVs and motorhome RVs provided by the Recreation Vehicle Industry Association. Industry retail sales data provided by Statistical Surveys, Inc.

(2)

Excludes the impact on net sales in 2026 from IEEPA tariff refunds passed through or expected to be passed through to customers.

(3)

Remaining availability under the revolving credit facility is subject to covenant restrictions.

(4)

Estimate excludes impact of restructuring costs, merger-related expenses, and IEEPA tariff refunds.

LCI INDUSTRIES

SUPPLEMENTARY INFORMATION

RECONCILIATION OF NON-GAAP MEASURES

(unaudited)

The following table reconciles net income to Adjusted EBITDA, net sales to adjusted net sales, and net income as a percentage of net sales to Adjusted EBITDA as a percentage of adjusted net sales.

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

(In thousands)

 

 

 

 

 

 

 

Net income

$

50,087

 

 

$

62,493

 

 

$

180,175

 

 

$

169,566

 

Interest expense, net

 

8,389

 

 

 

10,323

 

 

 

24,621

 

 

 

26,003

 

Provision for income taxes

 

18,220

 

 

 

21,533

 

 

 

63,573

 

 

 

59,848

 

Depreciation expense

 

15,999

 

 

 

16,706

 

 

 

50,019

 

 

 

50,195

 

Amortization expense

 

12,943

 

 

 

13,779

 

 

 

39,579

 

 

 

40,155

 

EBITDA

$

105,638

 

 

$

124,834

 

 

$

357,967

 

 

$

345,767

 

Loss on extinguishment of debt

 

—

 

 

 

806

 

 

 

—

 

 

 

8,859

 

Gain on sale of real estate

 

(1,681

)

 

 

(19,716

)

 

 

(2,235

)

 

 

(19,716

)

Restructuring costs

 

2,393

 

 

 

—

 

 

 

6,814

 

 

 

—

 

Merger expenses

 

5,120

 

 

 

—

 

 

 

19,244

 

 

 

—

 

Net impact of IEEPA tariff refunds

 

—

 

 

 

—

 

 

 

(15,972

)

 

 

—

 

Executive separation costs

 

—

 

 

 

—

 

 

 

—

 

 

 

3,193

 

Adjusted EBITDA

$

111,470

 

 

$

105,924

 

 

$

365,818

 

 

$

338,103

 

 

 

 

 

 

 

 

 

Net sales

$

992,483

 

 

$

1,036,477

 

 

$

3,051,675

 

 

$

3,189,317

 

IEEPA tariff refunds impact on net sales

 

—

 

 

 

—

 

 

 

88,792

 

 

 

—

 

Adjusted net sales

$

992,483

 

 

$

1,036,477

 

 

$

3,140,467

 

 

$

3,189,317

 

 

 

 

 

 

 

 

 

Net income as a percentage of net sales

 

5.0

%

 

 

6.0

%

 

 

5.9

%

 

 

5.3

%

Adjusted EBITDA as a percentage of adjusted net sales

 

11.2

%

 

 

10.2

%

 

 

11.6

%

 

 

10.6

%

The following table reconciles operating profit margin to adjusted operating profit margin.

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

2026

 

2025

 

2026

 

2025

Operating profit margin

7.6

%

 

7.3

%

 

8.7

%

 

7.7

%

Restructuring costs

0.2

%

 

—

%

 

0.2

%

 

—

%

Merger expenses

0.5

%

 

—

%

 

0.6

%

 

—

%

Net impact of IEEPA tariff refunds

—

%

 

—

%

 

(0.7

)%

 

—

%

Executive separation costs

—

%

 

—

%

 

—

%

 

0.1

%

Adjusted operating profit margin

8.3

%

 

7.3

%

 

8.8

%

 

7.8

%

The following table reconciles net income to adjusted net income and net income per diluted share to adjusted net income per adjusted diluted share (“Adjusted EPS”).

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

(In thousands, except per share amounts)

 

 

 

 

 

 

 

Net income

$

50,087

 

 

$

62,493

 

 

$

180,175

 

 

$

169,566

 

Loss on extinguishment of debt

 

—

 

 

 

806

 

 

 

—

 

 

 

8,859

 

Gain on sale of real estate

 

(1,681

)

 

 

(19,716

)

 

 

(2,235

)

 

 

(19,716

)

Restructuring costs

 

2,393

 

 

 

—

 

 

 

6,814

 

 

 

—

 

Merger expenses

 

5,120

 

 

 

—

 

 

 

19,244

 

 

 

—

 

Net impact of IEEPA tariff refunds, including interest income

 

(713

)

 

 

—

 

 

 

(20,377

)

 

 

—

 

Executive separation costs

 

—

 

 

 

—

 

 

 

—

 

 

 

3,193

 

Tax effect of adjustments

 

(1,229

)

 

 

4,531

 

 

 

(827

)

 

 

1,836

 

Adjusted net income

$

53,977

 

 

$

48,114

 

 

$

182,794

 

 

$

163,738

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding – diluted

 

24,417

 

 

 

24,466

 

 

 

24,376

 

 

 

25,004

 

 

 

 

 

 

 

 

 

Net income per common share – diluted

$

2.05

 

 

$

2.55

 

 

$

7.39

 

 

$

6.78

 

Loss on extinguishment of debt

 

—

 

 

 

0.03

 

 

 

—

 

 

 

0.35

 

Gain on sale of real estate

 

(0.07

)

 

 

(0.80

)

 

 

(0.09

)

 

 

(0.79

)

Restructuring costs

 

0.10

 

 

 

—

 

 

 

0.28

 

 

 

—

 

Merger expenses

 

0.21

 

 

 

—

 

 

 

0.79

 

 

 

—

 

Net impact of IEEPA tariff refunds, including interest income

 

(0.03

)

 

 

—

 

 

 

(0.84

)

 

 

—

 

Executive separation costs

 

—

 

 

 

—

 

 

 

—

 

 

 

0.13

 

Tax effect of adjustments

 

(0.05

)

 

 

0.19

 

 

 

(0.03

)

 

 

0.08

 

Adjusted net income per common share – diluted (Adjusted EPS)

$

2.21

 

 

$

1.97

 

 

$

7.50

 

 

$

6.55

 

In addition to reporting financial results in accordance with U.S. GAAP, the Company has provided the non-GAAP performance measures of Adjusted EBITDA, adjusted net sales, adjusted operating profit margin, Adjusted EBITDA as a percentage of adjusted net sales, adjusted net income, and Adjusted EPS to illustrate and improve comparability of its results from period to period. Adjusted EBITDA is defined as net income before interest expense, net, provision for income taxes, depreciation expense, amortization expense, loss on extinguishment of debt, gain on sale of real estate, restructuring costs, merger expenses, the net impact of IEEPA tariff refunds, and executive separation costs, as applicable, during the three and nine month periods ended September 30, 2026 and 2025. Adjusted net sales is defined as net sales adjusted for the reduction in net sales related to IEEPA tariff refunds passed through or expected to be passed through to customers, during the nine month period ended September 30, 2026. Adjusted operating profit margin is defined as operating profit margin adjusted for restructuring costs, merger expenses, the net impact of IEEPA tariff refunds, and executive separation costs, as applicable, during the three and nine month periods ended September 30, 2026 and 2025. Adjusted net income is defined as net income adjusted for loss on extinguishment of debt, gain on sale of real estate, restructuring costs, merger expenses, the net impact of IEEPA tariff refunds, including interest income, executive separation costs, and the related tax effects, as applicable, during the three and nine month periods ended September 30, 2026 and 2025. Adjusted EPS is defined as adjusted net income divided by weighted average common shares outstanding – diluted. The restructuring costs adjusted out of the non-GAAP measures relate to the Company’s plant consolidations at our U.S. glass and automotive aftermarket facilities. The Company considers these non-GAAP measures in evaluating and managing the Company’s operations and believes that discussion of results adjusted for these items is meaningful to investors because it provides a useful analysis of ongoing underlying operating trends. These measures are not in accordance with, nor are they substitutes for, GAAP measures, and they may not be comparable to similarly titled measures used by other companies.

Further, the Company has provided its outlook for full-year 2026 Adjusted EPS and adjusted operating profit margin in this release. The Company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to their most directly comparable GAAP financial measures because the Company is unable to provide, without unreasonable effort, a meaningful or accurate calculation or estimation of amounts that would be necessary for the reconciliation due to the complexity and inherent difficulty in forecasting and quantifying future amounts or when they may occur. The financial impact of such items is uncertain and is dependent on various factors, including timing, and could be material to the Company’s consolidated statements of income.

Lillian D. Etzkorn, CFO

(574) 535-1125

[email protected]

KEYWORDS: United States North America Indiana

INDUSTRY KEYWORDS: Retail Engineering Transportation Automotive Manufacturing Travel Manufacturing Aftermarket Other Transport Automotive Transport Sports Outdoors Specialty Recreational Vehicles

MEDIA:

Logo
Logo

Xunlei Limited Schedules 2026 Unaudited Third Quarter Earnings Release on November 12, 2026

SHENZHEN, China, Nov. 05, 2026 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2026 on November 12, 2026 before market open.

The earnings press release will be available on the Company’s investor relations page at https://ir.xunlei.com.

Conference Call

Xunlei’s management will host a conference call at 7:00 a.m. U.S. Eastern Time on November 12, 2026 (8:00 p.m. Beijing/Hong Kong Time), to discuss the Company’s quarterly results and recent business developments.

Conference Call Preregistration

Participant Online Registration:

https://register-conf.media-server.com/register/BIc2330d7a779c458bb50fe65ca3a3d5f6

Please register to join the conference using the link provided above and dial in 10 minutes before the call is scheduled to begin. Once registered, the participants will receive an email with personal PIN and dial-in information, and participants can choose to access either via Dial-In or Call Me. A kind reminder that “Call Me” does not work for Chinese numbers.

The Company will also broadcast a live audio webcast of the conference call. The webcast will be available at https://ir.xunlei.com. Following the earnings conference call, an archive of the call will be available at https://edge.media-server.com/mmc/p/okinc6yv

About Xunlei

Founded in 2003, Xunlei Limited (NASDAQ: XNET) is a leading technology company providing distributed cloud services in China. Xunlei provides a wide range of products and services across cloud acceleration and digital entertainment to deliver an efficient, smart and safe internet experience.

Contact:

Xunlei Limited Investor Relations

Email: [email protected]
Tel: +86 755 6111 1571
Website: https://ir.xunlei.com



Nexstar Media Group Reports Record Quarterly Net Revenue of $2.1 Billion

Nexstar Media Group Reports Record Quarterly Net Revenue of $2.1 Billion

Q3 Net Revenue Drives Net Income of $250 Million, Adjusted EBITDA of $756 Million, Net Cash Provided by Operating Activities of $680 Million and Adjusted Free Cash Flow of $443 Million

Delivered Record Q3 Political Advertising Revenue of $317 Million

Repaid $1.3 Billion of Debt Year-to-Date through Today and Returned $58 Million to Shareholders in Dividends in Q3

IRVING, Texas–(BUSINESS WIRE)–
Nexstar Media Group, Inc. (NASDAQ: NXST) (“Nexstar” or the “Company”) today reported financial results for the third quarter ended September 30, 2026 as summarized below. Please visit Nexstar’s website to view the full press release.

STATEMENT FROM PERRY A. SOOK, FOUNDER, CHAIRMAN AND CEO

“Nexstar delivered the highest quarterly net revenue in the Company’s history, reflecting the acquisition of TEGNA, Inc. and strong distribution and advertising revenue performance, including all-time high third-quarter political advertising revenue. The CW set a network record with its most-watched sports broadcast ever, as August’s New Mexico State – Florida State football game outperformed three of the major broadcast networks in primetime among Adults 25–54. NewsNation continues its momentum, growing total day viewership 9% year-over-year for the third quarter. Our strong operating performance for the first nine months of the year generated $1.1 billion in Adjusted Free Cash Flow, enabling us to reduce debt by $786 million and return $171 million to shareholders through dividends, while also funding ongoing investments in local news and sports programming. Looking ahead, we will continue to execute our playbook to drive long-term shareholder value while enhancing the programming, products and services that make Nexstar a leading choice for audiences and advertisers and an essential partner to networks and distributors.”

2026 Third Quarter Financial Summary

($ in millions)

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2026

 

2025

 

% Change

 

2026

 

2025

 

% Change

Distribution

 

$

1,091

 

 

$

709

 

 

53.9

 

$

3,044

 

 

$

2,204

 

 

38.1

 

Advertising

 

 

1,023

 

 

 

476

 

 

114.9

 

 

2,433

 

 

 

1,410

 

 

72.6

 

Other

 

 

19

 

 

 

13

 

 

46.2

 

 

45

 

 

 

46

 

 

(2.2

)

Net Revenue

 

$

2,133

 

 

$

1,198

 

 

78.0

 

$

5,522

 

 

$

3,660

 

 

50.9

 

Net Income

 

$

250

 

 

$

65

 

 

284.6

 

$

523

 

 

$

253

 

 

106.7

 

% Margin(1)

 

 

11.7

%

 

 

5.4

%

 

6.3

 

 

9.5

%

 

 

6.9

%

 

2.6

 

Adjusted EBITDA(2)

 

$

756

 

 

$

358

 

 

111.2

 

$

1,860

 

 

$

1,128

 

 

64.9

 

% Margin(1)

 

 

35.4

%

 

 

29.9

%

 

5.5

 

 

33.7

%

 

 

30.8

%

 

2.9

 

Net Cash Provided by Operating Activities

 

$

680

 

 

$

117

 

 

481.2

 

$

1,267

 

 

$

701

 

 

80.7

 

Adjusted Free Cash Flow(2)

 

$

443

 

 

$

166

 

 

166.9

 

$

1,101

 

 

$

615

 

 

79.0

(1)

Net Income margin is Net Income as a percentage of Net Revenue. Adjusted EBITDA margin is Adjusted EBITDA as a percentage of Net Revenue.

(2)

Please refer to the “Definitions and Disclosures Regarding Non-GAAP Financial Information” section herein and the reconciliations at the end of this press release.

Company and Business Highlights

  • Completed a multi-year affiliation agreement extending the FOXaffiliation in 41 markets. (August 2026)

  • TEGNA completed a multi-year agreementextending the ABC affiliation in 13 markets. (October 2026)
  • Nexstar and TEGNA each completed multi-year affiliation agreements extending CW affiliations in 66 and 8 markets, respectively. (August 2026)
  • TEGNA CEO Patrick Paolini appointed new operating and sales executives to the Company’s leadership team. (October 2026)
  • Ahead of the midterm elections, Nexstar’s local television stations produced 88 candidate debates and forums, connecting communities with candidates to discuss the issues that matter most, while providing candidates with an unmatched platform to reach voters.

  • Continued to advance The CW’s strategy to expand its audience and programming.

    • The CW ranked as the #9 rated English-language ad-supported network in Q3 2026. (September 2026)

    • Expanded The CW’s college football lineup with the addition of the San Diego County Credit Union Poinsettia Bowl and the Annual Holiday Bowl games. (August 2026)
    • Reached an exclusive multi-year media rights agreement with the National Hot Rod Association (NHRA) for The CWto broadcast the final seven races of the Mission Foods Drag Racing Seriesbeginning in September 2027. (September 2026)
  • NewsNation momentum continued, growing total day viewership 9% in the third quarter compared to the same quarter in 2025. (September 2026)

Financial Results

  • Net Revenue. Record quarterly net revenue of $2.13 billion, increased $935 million year-over-year, or 78.0%, primarily due to $765 million of incremental revenue from our acquisition of TEGNA and higher advertising and distribution revenue from our legacy business units.
  • Distribution Revenue. Third quarter distribution revenue of $1,091 million, increased $382 million, or 53.9%, versus the comparable prior year quarter, primarily reflecting $352 million of incremental revenue from the acquisition of TEGNA and higher revenue from our legacy business units due to increased rates, the impact of a one-time charge in the third quarter of 2025 which did not recur in the 2026 period, growth in vMVPD and other streaming subscribers, and the addition of CW affiliations on certain of our stations, partially offset by MVPD subscriber attrition and affiliation replacements on six stations previously affiliated with CBS.
  • Advertising Revenue. Third quarter advertising revenue of $1,023 million, increased $547 million, or 114.9%, from the comparable prior year quarter, primarily reflecting $405 million of incremental revenue from the acquisition of TEGNA and a $163 million increase in political advertising at our legacy business units, partially offset by lower non-political advertising due, in part, to crowd-out from political advertising. In total, Q3 political advertising revenue was $317 million, as 2026 is an election year.
  • Net Income. Third quarter net income of $250 million increased $185 million, or 284.6%, compared to the prior year quarter, primarily due to increased operating income from the acquisition of TEGNA and increased political advertising revenue generated at our legacy business units, partially offset by increased interest, income tax and one-time expenses, all in connection with the TEGNA transaction. Net income margin increased to 11.7% from 5.4% in the comparable prior year period.
  • Adjusted EBITDA. Third quarter Adjusted EBITDA of $756 million, increased $398 million, or 111.2%, compared to the prior year quarter reflecting $243 million of incremental Adjusted EBITDA from the acquisition of TEGNA and increased revenue at our legacy business units. Adjusted EBITDA margin was 35.4% compared to 29.9% in the comparable prior year period.
  • Net Cash Provided by Operating Activities. Third quarter Net Cash Provided by Operating Activities of $680 million, increased $563 million, or 481.2%, compared to the comparable prior year quarter, due primarily to an increase in net income and the impact of changes in operating assets and liabilities reflecting the timing of receipts and payments.
  • Adjusted Free Cash Flow. Third quarter Adjusted Free Cash Flow of $443 million, increased $277 million, or 166.9%, compared to the prior year quarter, due primarily to increased Adjusted EBITDA, partially offset by an increase in interest expense, capital expenditures and income tax payments, all primarily related to the acquisition of TEGNA.

Capital Allocation

  • In the third quarter of 2026, the Company used cash on hand and cash flow from operations to repay $350 million of debt and pay $58 million in dividends.

($ in millions, shares in thousands)

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

Cash Used For

 

 

 

 

 

 

 

 

Debt repayment

$

350

 

 

$

25

 

 

$

786

 

 

$

157

 

 

Acquisitions

 

–

 

 

 

–

 

 

 

3,657

 

 

 

22

 

 

Stockholder return

 

58

 

 

 

56

 

 

 

171

 

 

 

294

 

 

Common stock dividends

 

58

 

 

 

56

 

 

 

171

 

 

 

169

 

 

Stock repurchases

 

–

 

 

 

–

 

 

 

–

 

 

 

125

 

 

Shares Outstanding

 

 

 

 

 

 

 

 

End of period

 

30,818

 

 

 

30,324

 

 

 

30,818

 

 

 

30,324

 

 

Less: Beginning of period

 

30,806

 

 

 

30,315

 

 

 

30,328

 

 

 

30,621

 

 

Change in shares outstanding

 

12

 

 

 

9

 

 

 

490

 

 

 

(297

)

 

% Change

 

0.0

%

 

 

0.0

%

 

 

1.6

%

 

 

(1.0

%)

 

Debt, Cash and Leverage

  • As of September 30, 2026, the consolidated debt of Nexstar and Mission Broadcasting, Inc., an independently owned variable interest entity, was $11.4 billion, including senior secured debt of $8.6 billion.

  • As of September 30, 2026, the Company’s pro forma first lien net leverage ratio was 3.03x compared to a covenant ratio test of 4.75x and its total net leverage ratio was 4.04x, both calculated in accordance with the terms of its credit agreements which – beginning in the second quarter 2026 – exclude the synergies expected in connection with the acquisition of TEGNA(1).

  • Subsequent to September 30, through the date hereof, the Company repaid an additional $525 million of its secured credit facilities.

  • The table below summarizes the Company’s cash balances and debt obligations (net of financing costs, discounts and/or premiums) as of September 30, 2026 and December 31, 2025.

($ in millions)

 

September 30, 2026

 

December 31, 2025

 

Cash on Hand

 

$

446

 

$

280

 

Secured Credit Facilities

 

$

4,849

 

$

3,622

 

Secured Notes

 

 

3,797

 

 

–

 

Unsecured Notes

 

 

2,763

 

 

2,711

 

Total Debt

 

$

11,409

 

$

6,333

 

(1)

We are currently subject to a preliminary injunction that has impacted our ability to execute on synergies anticipated in connection with the acquisition of TEGNA. The trial on the merits of the plaintiffs’ claims is set for July 6, 2027. For synergies to be recognized for our covenant ratio test, they must be anticipated to be realized within 18 months from the date of the transaction, which date would be September 19, 2027 (the “Outside Synergies Date”). Given the limited time between the resolution of the trial and the Outside Synergies Date, we have removed the projected anticipated synergies from the leverage calculation. If conditions change, we will revisit this assessment and calculation.

Third Quarter Conference Call

Nexstar will host a conference call at 10:00 a.m. ET today. Senior management will discuss the financial results and host a question-and-answer session. The dial in number for the audio conference call is 1-877-407-9208 or 1-201-493-6784, conference ID 13762965 (domestic and international callers). Participants can also listen to a live webcast of the call through the “Events and Presentations” section under “Investor Relations” on Nexstar’s website at nexstar.tv. A webcast replay will be available for 90 days following the live event at nexstar.tv.

Forward-Looking Statements

This communication includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Forward-looking statements include information preceded by, followed by, or that includes the words “guidance,” “believes,” “expects,” “anticipates,” “could,” or similar expressions. For these statements, Nexstar claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this communication, concerning, among other things, future financial performance, including changes in net revenue, operating expenses and cash flow and the Company’s ability to integrate TEGNA and realize anticipated synergies, involve risks and uncertainties, and are subject to change based on various important factors, including the impact of changes in national and regional economies, the ability to service and refinance our outstanding debt, successful integration of business acquisitions (including achievement of synergies and cost reductions), the outcome of the pending litigations related to the TEGNA acquisition, pricing fluctuations in local and national advertising, future regulatory actions and conditions in the television stations’ operating areas, competition from others in the broadcast television markets, volatility in programming costs, the effects of governmental regulation of broadcasting, industry consolidation, technological developments and major world news events. Nexstar undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this communication might not occur. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. For more details on factors that could affect these expectations, please see Nexstar’s other filings with the Securities and Exchange Commission.

Definitions and Disclosures Regarding Non-GAAP Financial Information

Adjusted EBITDA is calculated as net income, plus or (minus): transaction, other one-time and restructuring expenses, stock-based compensation expense, depreciation and amortization of intangible assets (excluding amortization of broadcast rights), amortization of basis difference of equity method investments, (gain) loss on asset disposal, impairment charges, interest expense, net, loss on extinguishment of debt, pension and other postretirement plans costs (credit), income tax expense (benefit) and other operating and non-operating expense (income). We consider Adjusted EBITDA to be an indicator of our assets’ operating performance.

Free Cash Flow is calculated as net cash provided by operating activities less capital expenditures.

Adjusted Free Cash Flow is calculated as Free Cash Flow plus or (minus): transaction, other one-time and restructuring expenses, changes in operating assets and liabilities, net of acquisitions (excluding changes in income tax payable), taxes paid on sale of assets, pension and other postretirement plans costs (credit) and other items. We consider Adjusted Free Cash Flow to be an indicator of our liquidity. We consider Adjusted Free Cash Flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business that can be available for use in ongoing operations, debt payments, pension contributions, dividends, share repurchases, acquisitions and other items. Adjusted Free Cash Flow is not intended to represent the amount of cash flow available for discretionary expenditures as certain items and non-discretionary expenditures, such as changes in working capital, mandatory debt service requirements and pension contributions, are not deducted from this measure.

For a reconciliation of these non-GAAP financial measurements to the GAAP financial results cited in this news announcement, please see the supplemental tables at the end of this release.

About Nexstar Media Group, Inc.

Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that produces and distributes engaging local and national news, sports and entertainment content across its television and digital platforms. For more information, please visit nexstar.tv.

 

Nexstar Media Group, Inc.

Condensed Consolidated Statements of Operations

(in millions, except for share and per share amounts, unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

Net revenue

 

$

2,133

 

 

 

$

1,198

 

 

 

$

5,522

 

 

 

$

3,660

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Direct operating

 

 

936

 

 

 

 

562

 

 

 

 

2,477

 

 

 

 

1,670

 

Selling, general and administrative

 

 

316

 

 

 

 

202

 

 

 

 

862

 

 

 

 

607

 

Corporate

 

 

105

 

 

 

 

68

 

 

 

 

342

 

 

 

 

183

 

Amortization of broadcast rights

 

 

87

 

 

 

 

72

 

 

 

 

246

 

 

 

 

239

 

Depreciation and amortization of intangible assets

 

 

155

 

 

 

 

118

 

 

 

 

434

 

 

 

 

353

 

Other

 

 

2

 

 

 

 

1

 

 

 

 

2

 

 

 

 

1

 

Total operating expenses

 

 

1,601

 

 

 

 

1,023

 

 

 

 

4,363

 

 

 

 

3,053

 

Income from operations

 

 

532

 

 

 

 

175

 

 

 

 

1,159

 

 

 

 

607

 

Income from equity method investments, net

 

 

–

 

 

 

 

5

 

 

 

 

7

 

 

 

 

24

 

Interest expense, net

 

 

(186

)

 

 

 

(94

)

 

 

 

(495

)

 

 

 

(288

)

Pension and other postretirement plans credit, net

 

 

7

 

 

 

 

7

 

 

 

 

22

 

 

 

 

23

 

Loss on extinguishment of debt

 

 

(11

)

 

 

 

–

 

 

 

 

(21

)

 

 

 

(5

)

Other income, net

 

 

1

 

 

 

 

3

 

 

 

 

1

 

 

 

 

3

 

Income before income taxes

 

 

343

 

 

 

 

96

 

 

 

 

673

 

 

 

 

364

 

Income tax expense

 

 

(93

)

 

 

 

(31

)

 

 

 

(150

)

 

 

 

(111

)

Net income

 

 

250

 

 

 

 

65

 

 

 

 

523

 

 

 

 

253

 

Net loss attributable to noncontrolling interests

 

 

5

 

 

 

 

5

 

 

 

 

16

 

 

 

 

22

 

Net income attributable to Nexstar Media Group, Inc.

 

$

255

 

 

 

$

70

 

 

 

$

539

 

 

 

$

275

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share available to common stockholders:

 

 

 

 

 

 

 

 

 

Basic

 

$

7.97

 

 

 

$

2.16

 

 

 

$

16.86

 

 

 

$

8.66

 

Diluted

 

$

7.92

 

 

 

$

2.14

 

 

 

$

16.62

 

 

 

$

8.57

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

Basic (in thousands)

 

 

30,812

 

 

 

 

30,319

 

 

 

 

30,601

 

 

 

 

30,357

 

Diluted (in thousands)

 

 

31,013

 

 

 

 

30,649

 

 

 

 

31,030

 

 

 

 

30,696

 

 

Nexstar Media Group, Inc.

Condensed Consolidated Statements of Cash Flows

($ in millions, unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

523

 

 

 

$

253

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Amortization of broadcast rights

 

 

246

 

 

 

 

239

 

 

Depreciation and amortization of intangible assets

 

 

434

 

 

 

 

353

 

 

Stock-based compensation expense

 

 

80

 

 

 

 

58

 

 

Amortization of debt financing costs, debt discounts and premium

 

 

8

 

 

 

 

6

 

 

Loss on extinguishment of debt

 

 

21

 

 

 

 

5

 

 

Deferred income taxes

 

 

(56

)

 

 

 

(20

)

 

Payments for broadcast rights

 

 

(246

)

 

 

 

(249

)

 

Income from equity method investments, net

 

 

(7

)

 

 

 

(24

)

 

Distribution from equity method investments – return on capital

 

 

100

 

 

 

 

131

 

 

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

 

 

 

Accounts receivable

 

 

128

 

 

 

 

15

 

 

Prepaid and other current assets

 

 

26

 

 

 

 

6

 

 

Other noncurrent assets

 

 

8

 

 

 

 

3

 

 

Accounts payable

 

 

(12

)

 

 

 

(30

)

 

Accrued expenses and other current liabilities

 

 

89

 

 

 

 

44

 

 

Income tax payable

 

 

(14

)

 

 

 

(45

)

 

Other noncurrent liabilities

 

 

(62

)

 

 

 

(50

)

 

Other

 

 

1

 

 

 

 

6

 

 

Net cash provided by operating activities

 

 

1,267

 

 

 

 

701

 

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(113

)

 

 

 

(94

)

 

Payments for acquisitions, net of cash acquired

 

 

(3,341

)

 

 

 

(22

)

 

Proceeds received from life insurance policies

 

 

55

 

 

 

 

1

 

 

Proceeds from disposal of property and equipment

 

 

12

 

 

 

 

1

 

 

Other investing activities, net

 

 

(5

)

 

 

 

(4

)

 

Net cash used in investing activities

 

 

(3,392

)

 

 

 

(118

)

 

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from debt issuance, net of debt discounts

 

 

11,106

 

 

 

 

3,393

 

 

Repayments of long-term debt

 

 

(8,498

)

 

 

 

(3,568

)

 

Payments for debt financing costs

 

 

(107

)

 

 

 

(2

)

 

Premium paid on debt extinguishment

 

 

(13

)

 

 

 

–

 

 

Purchase of treasury stock

 

 

–

 

 

 

 

(125

)

 

Common stock dividends paid

 

 

(171

)

 

 

 

(169

)

 

Payments for capitalized software obligations

 

 

(7

)

 

 

 

(14

)

 

Cash paid for shares withheld for taxes

 

 

(18

)

 

 

 

–

 

 

Other financing activities, net

 

 

(1

)

 

 

 

(6

)

 

Net cash provided by (used in) financing activities

 

 

2,291

 

 

 

 

(491

)

 

Net increase in cash and cash equivalents

 

 

166

 

 

 

 

92

 

 

Cash and cash equivalents at beginning of period

 

 

280

 

 

 

 

144

 

 

Cash and cash equivalents at end of period

 

$

446

 

 

 

$

236

 

 

 

Nexstar Media Group, Inc.

Reconciliation of Adjusted EBITDA (Non-GAAP Measure)

($ in millions, unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

250

 

 

 

$

65

 

 

 

$

523

 

 

 

$

253

 

 

Add (Less):

 

 

 

 

 

 

 

 

 

 

 

 

Transaction, other one-time and restructuring expenses(1)

 

 

30

 

 

 

 

23

 

 

 

 

125

 

 

 

 

33

 

 

Stock-based compensation expense(2)

 

 

20

 

 

 

 

19

 

 

 

 

80

 

 

 

 

58

 

 

Depreciation and amortization of intangible assets

 

 

155

 

 

 

 

118

 

 

 

 

434

 

 

 

 

353

 

 

Amortization of basis difference of equity method investments

 

 

18

 

 

 

 

18

 

 

 

 

53

 

 

 

 

53

 

 

Interest expense, net

 

 

186

 

 

 

 

94

 

 

 

 

495

 

 

 

 

288

 

 

Loss on extinguishment of debt

 

 

11

 

 

 

 

–

 

 

 

 

21

 

 

 

 

5

 

 

Pension and other postretirement plans credit, net

 

 

(7

)

 

 

 

(7

)

 

 

 

(22

)

 

 

 

(23

)

 

Income tax expense

 

 

93

 

 

 

 

31

 

 

 

 

150

 

 

 

 

111

 

 

Other

 

 

–

 

 

 

 

(3

)

 

 

 

1

 

 

 

 

(3

)

 

Adjusted EBITDA

 

$

756

 

 

 

$

358

 

 

 

$

1,860

 

 

 

$

1,128

 

 

(1)

Primarily includes legal and other direct expenses associated with our acquisition of TEGNA, direct expenses associated with financing transactions, severance and other direct expenses associated with restructuring activities.

(2) 

Includes $18 million of accelerated stock-based compensation related to TEGNA acquisition restructuring activities in Q2 2026.

 

Nexstar Media Group, Inc.

Reconciliation of Free Cash Flow and Adjusted Free Cash Flow (Non-GAAP Measure)

($ in millions, unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

$

680

 

 

 

$

117

 

 

 

$

1,267

 

 

 

$

701

 

 

 

Add (Less):

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(46

)

 

 

 

(30

)

 

 

 

(113

)

 

 

 

(94

)

 

 

Free Cash Flow

 

$

634

 

 

 

$

87

 

 

 

$

1,154

 

 

 

$

607

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Add (Less):

 

 

 

 

 

 

 

 

 

 

 

 

 

Transaction, other one-time and restructuring expenses(1)

 

 

30

 

 

 

 

23

 

 

 

 

147

 

 

 

 

33

 

 

 

Changes in operating assets and liabilities(2)

 

 

(258

)

 

 

 

75

 

 

 

 

(163

)

 

 

 

57

 

 

 

Changes in income tax payable(3)

 

 

36

 

 

 

 

(7

)

 

 

 

(14

)

 

 

 

(45

)

 

 

Pension and other postretirement plans credit, net

 

 

(7

)

 

 

 

(7

)

 

 

 

(22

)

 

 

 

(23

)

 

 

Other(4)

 

 

8

 

 

 

 

(5

)

 

 

 

(1

)

 

 

 

(14

)

 

 

Adjusted Free Cash Flow

 

$

443

 

 

 

$

166

 

 

 

$

1,101

 

 

 

$

615

 

 

 

(1)

Primarily includes legal and other direct expenses associated with our acquisition of TEGNA, direct expenses associated with financing transactions, severance and other direct expenses associated with restructuring activities.

(2)

Removes the impact of changes in operating assets and liabilities (including changes in income tax payable), net of acquisitions.

(3)

Includes changes in income tax payable to reflect all tax payments.

(4)

Primarily include payments for capitalized software obligations, proceeds from disposal of assets and insurance recoveries (excluding $11 million proceeds from sale of certain real estate property in Q2 2026), and $3 million of tax payments in Q3 2026 related to the sale of such real estate asset.

 

Investor Contacts:

Lee Ann Gliha

EVP and Chief Financial Officer

Nexstar Media Group, Inc.

972/373-8800

Joe Jaffoni, Jennifer Neuman

JCIR

212/835-8500 or [email protected]

Media Contact:

Gary Weitman

EVP and Chief Communications Officer

Nexstar Media Group, Inc.

972/373-8800 or [email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Advertising Entertainment Communications Technology TV and Radio Audio/Video Media

MEDIA:

Logo
Logo

CareCloud Delivers Most Profitable Quarter in Company History: Record GAAP Net Income, Record GAAP EPS and Record adjusted EBITDA

SOMERSET, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD) (“CareCloud” or the “Company”), a leader in AI-powered healthcare technology and revenue cycle management solutions for medical practices and health systems nationwide, today announced record financial results for the quarter ended September 30, 2026. CareCloud delivered the highest quarterly profitability in its history: record GAAP net income of $4.7 million, up 54% year over year from $3.1 million; record GAAP EPS of $0.10, up 150% from $0.04; and record adjusted EBITDA of $9.9 million, up 28% from $7.7 million in the third quarter of 2025.

Third Quarter 2026 Highlights

  • Revenue of $33.7 million, compared to $31.1 million in Q3 2025, an increase of 9% year over year
  • Record GAAP net income of $4.7 million, compared to $3.1 million in Q3 2025, an increase of 54% year over year
  • Record net income attributable to common shareholders of $4.2 million, compared to $1.7 million in Q3 2025, an increase of 147% year over year
  • Record GAAP EPS of $0.10 per share, compared to $0.04 per share in Q3 2025, an increase of 150% year over year
  • Record adjusted EBITDA of $9.9 million, compared to $7.7 million in Q3 2025, an increase of 28% year over year

Year-to-date 2026 Highlights

  • Revenue of $96.9 million, compared to $86.1 million in the same period last year, an increase of 13%
  • GAAP net income of $6.8 million, compared to $7.9 million in the same period last year
  • Net income attributable to common shareholders of $3.9 million, compared to $2.4 million in the same period last year
  • GAAP EPS of $0.09 per share, compared to GAAP EPS of $0.07 per share in the same period last year
  • Adjusted EBITDA of $21.2 million, compared to $19.9 million in the same period last year

Recent Accomplishments

  • Record Quarterly Profitability. Q3 set all-time quarterly records across several key profitability measures including: GAAP net income of $4.7 million, GAAP EPS of $0.10 and adjusted EBITDA of $9.9 million (a 29% margin), up 54%, 150% and 28% year over year, respectively. Q3 GAAP EPS alone matched CareCloud’s GAAP EPS for all of 2025. Q3 was the Company’s 10th consecutive quarter of positive GAAP net income.
  • Reduced debt by $7.4 million, including a $0.8 million prepayment. On May 15, 2026, CareCloud redeemed all of its Series B Preferred Stock for $41.6 million with proceeds from its credit facility, replacing perpetual preferred stock with lower-cost debt that amortizes monthly. As of November 2, the term loan stands at $34.2 million. Additionally, the $9 million borrowed on the line of credit was repaid. The Company intends to make additional prepayments on the term loan as cash flow permits.
  • AI and Automation driving efficiency. CareCloud has built AI into its claims processing. Over the past three months, it cut manual claim touches by 44% in the division that serves the majority of its RCM clients, allowing teams to handle more volume without adding headcount.
  • Compliance as a cross-sell engine. Empower, acquired in May 2026, recently reversed more than $1 million in alleged payers overpayments for a client, and has already opened doors to new CareCloud RCM signings with an MSO and a wound care practice. On October 21, CareCloud appointed Empower founder Mitchell Brie, CHC, as Chief Compliance Officer to scale compliance services across its more than 40,000 providers, and plans to launch a SaaS compliance offering in late Q4 2026.

Management Commentary

“Record GAAP net income, record GAAP EPS and record adjusted EBITDA: the third quarter was the most profitable in CareCloud’s history, and the $0.10 we earned per share in a single quarter matched what we earned in all of 2025. With ten consecutive profitable quarters behind us, we are putting those earnings to work, paying down debt every month while investing in the AI-enabled solutions, compliance platform and cross-selling opportunity across the customer base that will drive our next phase of growth. That momentum is why we are reaffirming our full-year guidance.”

— Stephen Snyder, Chief Executive Officer, CareCloud

“LailaCare shows what our AI strategy looks like in practice: we are building AI-enabled workflows for enterprise clients, and we recognized our first revenue from that work this quarter. Inside our own operations, AI and automation have cut manual claim touches by 44% in just three months, so our teams handle more volume with the same headcount, and that efficiency helped power this quarter’s record adjusted EBITDA. Our focus now is converting those capabilities into cross-sell revenue across our client base.”

— A. Hadi Chaudhry, Chief Strategy Officer, CareCloud

“Record earnings and a simpler capital structure are working together for common shareholders. Net income attributable to common shareholders more than doubled to $4.2 million year over year, and the cash our business produces is steadily reducing our debt, so more of CareCloud’s value belongs to our shareholders every quarter.”

— Bonnie Boyer, Chief Financial Officer, CareCloud

2026 Outlook: Priorities remain clear

Third quarter adjusted EBITDA grew 28% year over year to a record $9.9 million, alongside record GAAP net income and GAAP EPS. Third quarter revenue less direct operating costs rose to 50.5% of revenue from 47.8%, driven by a shift toward higher-margin offerings and a more efficient core business. We are investing in organic growth through AI-enabled technology and process transformation for enterprise clients, our planned late-Q4 SaaS compliance launch, and cross-selling across more than 40,000 providers, while using free cash flow to reduce debt.

The Company is reaffirming its guidance for calendar year 2026.

For the Fiscal Year Ending December 31, 2026 Full Year 2026 Guidance
Revenue $128 – $132 million
Adjusted EBITDA $29 – $31 million
GAAP Net Income Per Share (EPS) $0.20 – $0.23


Revenue guidance is based on management’s expectations for contributions from existing clients, together with cross-selling and other organic and inorganic growth. GAAP EPS guidance of $0.20–$0.23 represents a 100-130% increase from the $0.10 achieved in full year 2025. Adjusted EBITDA guidance of $29–$31 million represents growth of approximately 5–13% over 2025 actuals of $27.5 million. The Company’s ability to achieve guidance is contingent, among other things, on the continued performance of its existing and new customers, and an impairment to the relationship of one or more of these customers could have a material adverse effect on the Company’s performance.

Conference Call Information

CareCloud management will host a live conference call today, November 5, 2026, at 8:30 a.m. Eastern Time to discuss third quarter 2026 results and the Company’s 2026 strategy.

Webcast:
ir.carecloud.com/events

Dial-in (Audio Only): 201-389-0920 | Reference: “CareCloud, Inc. Third Quarter 2026 Results Conference Call.”

Replay Dial-in: 412-317-6671 | Access Code: 13762600 (available approximately 3 hours after the call).

About CareCloud

CareCloud brings disciplined innovation to the business of healthcare. Our suite of AI and technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at carecloud.com.

Follow CareCloud on LinkedIn, X and Facebook.

For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud’s management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.

Contacts

Company Contact:   Investor Contact:
     
Bonnie Boyer   Stephen Snyder
Chief Financial Officer   Chief Executive Officer
CareCloud, Inc.   CareCloud, Inc.
[email protected]   
[email protected]
     

Use of Non-GAAP Financial Measures

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we use and discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investor Relations section of our web site at ir.carecloud.com.

Forward-Looking Statements

This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,” “forecasts,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology.

Our operations involve risks and uncertainties, many of which are outside our control and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of pandemics on our financial performance and business activities and the expected results from the integration of our acquisitions.

These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies’ products and services competitive with ours, manage and keep our information systems secure and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

CARECLOUD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2026 AND DECEMBER 31, 2025
($ in thousands, except share and per share amounts)
             
      September 30,       December 31,  
      2026       2025  
      (Unaudited)          
ASSETS                
Current assets:                
Cash   $ 4,636     $ 3,117  
Restricted cash     –       500  
Accounts receivable – net     16,529       15,062  
Contract asset     3,063       3,664  
Inventory     512       507  
Current assets – related party     16       16  
Prepaid expenses and other current assets     3,636       2,872  
Total current assets     28,392       25,738  
Property and equipment – net     6,836       7,775  
Operating lease right-of-use assets     5,245       3,106  
Intangible assets – net     14,261       18,968  
Goodwill     31,631       31,442  
Other assets     734       569  
TOTAL ASSETS   $ 87,099     $ 87,598  
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities:                
Accounts payable   $ 6,204     $ 6,937  
Accrued compensation     3,859       4,136  
Accrued expenses     5,703       5,970  
Operating lease liability     1,677       927  
Deferred revenue     3,944       4,148  
Term and other loans     10,597       728  
Contingent consideration     256       909  
Dividend payable     392       668  
Total current liabilities     32,632       24,423  
Term and other loans     26,698       441  
Contingent consideration     192       232  
Operating lease liability     3,835       2,187  
Deferred revenue     1,023       809  
Deferred tax liability     95       –  
Total liabilities     64,475       28,092  
COMMITMENTS AND CONTINGENCIES                
SHAREHOLDERS’ EQUITY:                
Preferred stock, $0.001 par value – authorized 7,000,000 shares. Series A, issued and outstanding 984,530 shares at September 30, 2026 and December 31, 2025. Series B, issued and outstanding 0 and 1,511,372 shares at September 30, 2026 and December 31, 2025, respectively.     1       2  
Common stock, $0.001 par value – authorized 85,000,000 shares. Issued 43,289,658 and 43,178,748 shares at September 30, 2026 and December 31, 2025, respectively. Outstanding 42,548,859 and 42,437,949 shares at September 30, 2026 and December 31, 2025, respectively.     43       43  
Additional paid-in capital     76,196       119,936  
Accumulated deficit     (49,061 )     (55,832 )
Accumulated other comprehensive loss     (3,893 )     (3,981 )
Less: 740,799 common shares held in treasury, at cost at September 30, 2026 and December 31, 2025     (662 )     (662 )
Total shareholders’ equity     22,624       59,506  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   $ 87,099     $ 87,598  

CARECLOUD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
($ in thousands, except share and per share amounts)
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
NET REVENUE   $ 33,725     $ 31,067     $ 96,875     $ 86,076  
OPERATING EXPENSES:                                
Direct operating costs     16,709       16,224       51,016       46,168  
Selling and marketing     1,305       1,123       4,019       3,372  
General and administrative     4,951       4,887       15,817       13,577  
Research and development     1,052       1,584       5,662       3,839  
Change in contingent consideration     (32 )     –       (9 )     –  
Depreciation and amortization     3,165       4,022       10,933       10,741  
Restructuring costs     –       17       –       154  
Total operating expenses     27,150       27,857       87,438       77,851  
OPERATING INCOME     6,575       3,210       9,437       8,225  
OTHER:                                
Interest income     81       95       164       188  
Interest expense     (1,801 )     (147 )     (2,674 )     (273 )
Other (expense) income – net     (1 )     (55 )     125       (104 )
INCOME BEFORE PROVISION FOR INCOME TAXES     4,854       3,103       7,052       8,036  
Income tax provision     127       43       281       126  
NET INCOME   $ 4,727     $ 3,060     $ 6,771     $ 7,910  
                                 
Preferred stock dividend     538       1,365       2,844       5,541  
NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS   $ 4,189     $ 1,695     $ 3,927     $ 2,369  
                                 
Net income per common share: basic and diluted   $ 0.10     $ 0.04     $ 0.09     $ 0.07  
Weighted-average common shares used to compute basic and diluted income per share     42,528,315       42,368,914       42,498,112       36,236,128  

CARECLOUD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
($ in thousands)
             
      2026       2025  
OPERATING ACTIVITIES:                
 Net income   $ 6,771     $ 7,910  
 Adjustments to reconcile net income to net cash provided by operating activities:                
 Depreciation and amortization     11,083       10,936  
 Lease amortization     1,317       1,319  
 Provision for expected credit losses     409       343  
 Provision for deferred income taxes     95       –  
 Foreign exchange loss     13       60  
 Interest accretion     1,254       326  
 Change in contingent consideration     (9 )     –  
 Stock-based compensation expense     193       307  
 Changes in operating assets and liabilities:                
    Accounts receivable     (1,876 )     (796 )
    Contract asset     601       461  
 Inventory     (5 )     (31 )
 Other assets     (812 )     (2,581 )
 Accounts payable and other liabilities     (2,684 )     2,124  
 Deferred revenue     (23 )     (492 )
 Net cash provided by operating activities     16,327       19,886  
INVESTING ACTIVITIES:                
 Purchases of property and equipment     (1,265 )     (2,655 )
 Capitalized software and other intangible assets     (3,146 )     (2,505 )
 Payments for acquisitions     (967 )     (16,040 )
 Net cash used in investing activities     (5,378 )     (21,200 )
FINANCING ACTIVITIES:                
 Preferred stock dividends paid     (6,974 )     (4,821 )
 Payment of contingent consideration     (677 )     (53 )
 Payment of tax withholding on stock issued to employees     (2 )     (22 )
 Proceeds from term loan     39,756       –  
 Repayments of term and other loans     (3,874 )     (378 )
 Redemption of Series B Preferred Stock     (38,169 )     –  
 Proceeds from line of credit     9,000       8,343  
 Repayments of line of credit     (9,000 )     (1,843 )
 Net cash (used in) provided by financing activities     (9,940 )     1,226  
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND RESTRICTED CASH     10       16  
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH     1,019       (72 )
CASH AND RESTRICTED CASH – Beginning of the period     3,617       5,145  
CASH AND RESTRICTED CASH – End of the period   $ 4,636     $ 5,073  
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:                
 Conversion of preferred stock and accrued dividends to common stock   $ –     $ 2,435  
 Dividends declared, not paid   $ 392     $ 714  
SUPPLEMENTAL INFORMATION – Cash paid during the period for:                
   Income taxes   $ 171     $ 172  
   Interest   $ 1,376     $ 64  


RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES (UNAUDITED)

The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”

While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.

Adjusted EBITDA to GAAP Net Income

Set forth below is a reconciliation of our “adjusted EBITDA” to our GAAP net income.

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
    ($ in thousands)  
Net revenue   $ 33,725     $ 31,067     $ 96,875     $ 86,076  
                                 
GAAP net income     4,727       3,060       6,771       7,910  
                                 
Provision for income taxes     127       43       281       126  
Net interest expense     1,720       52       2,510       85  
Foreign exchange loss / other expense     7       60       93       120  
Stock-based compensation expense     65       88       193       307  
Depreciation and amortization     3,189       4,022       10,957       10,741  
Change in contingent consideration     (32 )     –       (9 )     –  
Transaction and integration costs     77       391       401       414  
Restructuring costs     –       17       –       154  
Adjusted EBITDA   $ 9,880     $ 7,733     $ 21,197     $ 19,857  



Non-GAAP Adjusted Operating Income to GAAP Operating Income

Set forth below is a reconciliation of our non-GAAP “adjusted operating income” and non-GAAP “adjusted operating margin” to our GAAP operating income and GAAP operating margin.

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
    ($ in thousands)  
Net revenue   $ 33,725     $ 31,067     $ 96,875     $ 86,076  
                                 
GAAP net income     4,727       3,060       6,771       7,910  
Provision for income taxes     127       43       281       126  
Net interest expense     1,720       52       2,510       85  
Other expense (income) – net     1       55       (125 )     104  
GAAP operating income     6,575       3,210       9,437       8,225  
GAAP operating margin     19.5 %     10.3 %     9.7 %     9.6 %
                                 
Stock-based compensation expense     65       88       193       307  
Amortization of purchased intangible assets     939       794       2,812       1,076  
Transaction and integration costs     77       391       401       414  
Change in contingent consideration     (32 )     –       (9 )     –  
Restructuring costs     –       17       –       154  
Non-GAAP adjusted operating income   $ 7,624     $ 4,500     $ 12,834     $ 10,176  
Non-GAAP adjusted operating margin     22.6 %     14.5 %     13.2 %     11.8 %



Non-GAAP Adjusted Net Income to GAAP Net Income

Set forth below is a reconciliation of our non-GAAP “adjusted net income” and non-GAAP “adjusted net income per share” to our GAAP net income and GAAP net income per share.

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
    ($ in thousands )  
GAAP net income   $ 4,727     $ 3,060     $ 6,771     $ 7,910  
                                 
Foreign exchange loss / other expense     7       60       93       120  
Stock-based compensation expense     65       88       193       307  
Amortization of purchased intangible assets     939       794       2,812       1,076  
Transaction and integration costs     77       391       401       414  
Change in contingent consideration     (32 )     –       (9 )     –  
Restructuring costs     –       17       –       154  
Income tax expense related to goodwill     45       –       95       –  
Non-GAAP adjusted net income   $ 5,828     $ 4,410     $ 10,356     $ 9,981  

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
GAAP net income attributable to common shareholders, per share   $ 0.10     $ 0.04     $ 0.09     $ 0.07  
Impact of preferred stock dividend     0.01       0.03       0.07       0.12  
Net income per end-of-period share     0.11       0.07       0.16       0.19  
                                 
Foreign exchange loss / other expense     0.00       0.00       0.00       0.00  
Stock-based compensation expense     0.00       0.00       0.00       0.01  
Amortization of purchased intangible assets     0.03       0.02       0.07       0.03  
Transaction and integration costs     0.00       0.01       0.01       0.01  
Change in contingent consideration     0.00       –       0.00       –  
Restructuring costs     –       0.00       –       0.00  
Income tax expense related to goodwill     0.00       –       0.00       0.00  
Non-GAAP adjusted earnings per share   $ 0.14     $ 0.10     $ 0.24     $ 0.24  
                                 
End-of-period common shares     42,548,859       42,397,039       42,548,859       42,397,039  


For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding as of September 30, 2026 and 2025. Non-GAAP adjusted earnings per share does not take into account dividends declared or earned on preferred stock.

Net cash provided by operating activities to free cash flow

Set forth below is a reconciliation of our non-GAAP “free cash flow” to our GAAP net cash provided by operating activities.

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
    ($ in thousands)  
Net cash provided by operating activities   $ 5,643     $ 7,365     $ 16,327     $ 19,886  
                                 
Purchases of property and equipment     (328 )     (869 )     (1,265 )     (2,655 )
Capitalized software and other intangible assets     (1,526 )     (828 )     (3,146 )     (2,505 )
Free cash flow   $ 3,789     $ 5,668     $ 11,916     $ 14,726  
                                 
Net cash used in investing activities 1   $ (2,140 )   $ (17,697 )   $ (5,378 )   $ (21,200 )
Net cash (used in) provided by financing activities   $ (12,264 )   $ 4,920     $ (9,940 )   $ 1,226  


1. Net cash in investing includes payments for acquisitions, purchases of property and equipment and capitalized software and other intangible assets. Purchases of property and equipment and capitalized software and other intangible assets are included in our computation of free cash flow.

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of CareCloud and compare it against past periods, make operating decisions and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

Management uses adjusted EBITDA, adjusted operating income, adjusted operating margin, and non-GAAP adjusted net income to provide an understanding of aspects of operating results before the impact of investing and financing charges and income taxes. Adjusted EBITDA may be useful to an investor in evaluating our operating performance and liquidity because this measure excludes non-cash expenses as well as expenses pertaining to investing or financing transactions. Management defines “adjusted EBITDA” as the sum of GAAP net income (loss) before provision for (benefit from) income taxes, net interest expense, other (income) expense, stock-based compensation expense, depreciation and amortization, integration costs, transaction costs, impairment charges, restructuring costs and changes in contingent consideration.

Management defines “non-GAAP adjusted operating income” as the sum of GAAP operating income (loss) before stock-based compensation expense, amortization of purchased intangible assets, integration costs, transaction costs, impairment charges, restructuring costs and changes in contingent consideration, and “non-GAAP adjusted operating margin” as non-GAAP adjusted operating income divided by net revenue.

Management defines “non-GAAP adjusted net income” as the sum of GAAP net income (loss) before stock-based compensation expense, amortization of purchased intangible assets, other (income) expense, integration costs, transaction costs, impairment charges, restructuring costs, changes in contingent consideration, any tax impact related to these preceding items and income tax expense related to goodwill, and “non-GAAP adjusted net income per share” as non-GAAP adjusted net income divided by common shares outstanding at the end of the period, including the shares which were issued but are subject to forfeiture and considered contingent consideration.

Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.

In addition to items routinely excluded from non-GAAP EBITDA, management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

Foreign exchange loss/other expense. Other expense is excluded because foreign currency gains and losses and other non-operating expenses are expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expense is partially outside of our control. Foreign currency gains and losses are based on global market factors which are unrelated to our performance during the period in which the gains and losses are recorded.

Stock-based compensation expense. Stock-based compensation expense is excluded because this is primarily a non-cash expenditure that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred. Stock-based compensation expense includes cash-settled awards based on changes in the stock price.

Amortization of purchased intangible assets. Purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

Transaction costs. Transaction costs are upfront costs related to acquisitions and related transactions, such as brokerage fees, pre-acquisition accounting costs and legal fees, and other upfront costs related to specific transactions. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Integration costs. Integration costs are severance payments for certain employees relating to our acquisitions and exit costs related to terminating leases and other contractual agreements. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Contingent consideration. Contingent consideration represents the portion of consideration payable to the seller of some of our acquisitions, the amount of which is based on the achievement defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Restructuring costs. Restructuring costs primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Income tax expense related to goodwill. Income tax expense resulting from the amortization of goodwill related to our acquisitions represents a charge to record the tax effect resulting from amortizing goodwill over 15 years for tax purposes. Goodwill is not amortized for GAAP reporting. This expense is not anticipated to result in a cash payment.

Free cash flow. Management believes that free cash flow, which measures our ability to generate additional cash from our business operations, is an important financial measure for use in evaluating the Company’s financial performance. Free cash flow should be considered in addition to, rather than as a substitute for, consolidated net operating results as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. Additionally, the Company’s definition of free cash flow is limited, in that it does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the payments required for debt service and other contractual obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as a measure that provides supplemental information to our condensed consolidated statements of cash flows.



Frontdoor Reports Third Quarter 2026 Results

Frontdoor Reports Third Quarter 2026 Results

Revenue Increased 6% to $655 Million;

Net Income Increased 10% to $116 Million, Adjusted EBITDA(2) Increased 5% to $205 Million;

EPS(1) and Adjusted EPS(1),(2) Increased 16% to $1.65 and 15% to $1.81, Respectively;

Company Announces New $1 Billion Share Repurchase Authorization

MEMPHIS, Tenn.–(BUSINESS WIRE)–Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home warranties and new home builder warranties, today announced its third-quarter 2026 results.

Third-Quarter 2026 Summary

  • Number of home warranties grew 1% to 2.14 million
  • Revenue increased 6% to $655 million
  • Gross profit margin of 55%
  • Net Income and EPS(1) increased 10% to $116 million and 16% to $1.65, respectively
  • Adjusted EBITDA(2) increased 5% to $205 million
  • Generated $318 million of Operating Cash Flow and $298 million of Free Cash Flow(2)
  • Completed $259 million of share repurchases through September, up over 30% year-to-date

Raising Full-Year 2026 Outlook

  • Revenue of $2.205 billion to $2.215 billion
  • Adjusted EBITDA(2) of $590 million to $600 million

“I am proud of how our team produced strong third-quarter results while providing exceptional service for our members during the hottest summer on record,” said Chairman and Chief Executive Officer Bill Cobb. “Our team continues to rise to the challenge and find new ways to improve our operations and elevate the member experience. These outcomes reflect the value we provide homeowners, the dedication of our people, and the durability of our business model.”

“We delivered higher revenue, Adjusted EBITDA and earnings per share again in the third quarter,” said Chief Financial Officer Jason Bailey. “Our capital-light business continued to generate strong cash flows and enabled us to accelerate share repurchases in the third-quarter. We now expect to complete our current authorization in November. As a result, our Board of Directors approved a new $1 billion authorization, which reflects our confidence in the business and underscores our commitment to returning excess cash to shareholders.”

Third-Quarter 2026 Results

Financial Results

 

 

Three Months Ended

 

 

September 30,

(In millions, except per share data)

 

2026

 

2025

 

Change

Revenue

 

$

655

 

 

$

618

 

 

 

6

%

Gross Profit

 

 

362

 

 

 

353

 

 

 

3

%

Net Income

 

 

116

 

 

 

106

 

 

 

10

%

Earnings per Share(1)

 

 

1.65

 

 

 

1.42

 

 

 

16

%

Adjusted Net Income(2)

 

 

127

 

 

 

117

 

 

 

8

%

Adjusted Earnings per Share(1),(2)

 

 

1.81

 

 

 

1.58

 

 

 

15

%

Adjusted EBITDA(2)

 

 

205

 

 

 

195

 

 

 

5

%

Number of Home Warranties

 

 

2.14

 

 

 

2.11

 

 

 

1

%

Revenue by Customer Channel

 

 

Three Months Ended

 

 

September 30,

(In millions)

 

2026

 

2025

 

Change

Renewals

 

$

479

 

 

$

461

 

 

 

4

%

Real estate (First-Year)

 

 

44

 

 

 

43

 

 

 

3

%

Direct-to-consumer (First-Year)

 

 

54

 

 

 

54

 

 

 

(1

)%

Other

 

 

78

 

 

 

59

 

 

 

32

%

Total

 

$

655

 

 

$

618

 

 

 

6

%

Revenue increased 6% to $655 million and was comprised of 3% from higher realized price and 3% from higher volume.

  • Renewal revenue increased 4%, driven by higher realized price;

  • Real estate revenue increased 3%, due to higher volume;

  • Direct-to-consumer revenue declined 1%, due to lower realized price from our promotional pricing strategy that was partially offset by higher volume from growth in the number of new home warranty members;

  • Other revenue increased 32%, primarily due to the New HVAC upgrade program.

Period-over-Period Net Income and Adjusted EBITDA(2) Bridge

(In millions)

 

Net Income

 

 

Adjusted

EBITDA

Three Months Ended September 30, 2025

 

$

 

106

 

 

 

$

 

195

 

Impact of change in revenue

 

 

 

17

 

 

 

 

 

17

 

Contract claims costs

 

 

 

(7

)

 

 

 

 

(7

)

Sales and marketing costs

 

 

 

(4

)

 

 

 

 

(4

)

Customer service costs

 

 

 

(1

)

 

 

 

 

(1

)

Stock-based compensation expense

 

 

 

(1

)

 

 

 

 

—

 

Other general and administrative costs

 

 

 

6

 

 

 

 

 

6

 

Depreciation and amortization expense

 

 

 

2

 

 

 

 

 

—

 

Interest expense

 

 

 

1

 

 

 

 

 

—

 

Provision for income taxes

 

 

 

(1

)

 

 

 

 

—

 

Other

 

 

 

(1

)

 

 

 

 

(1

)

Three Months Ended September 30, 2026

 

$

 

116

 

 

 

$

 

205

 

Third-quarter 2026 Net Income increased 10% to $116 million and Adjusted EBITDA(2) increased 5% to $205 million. The table above shows the change versus the prior-year period, and includes:

  • $17 million from higher revenue conversion(3).

  • Contract claims costs(4) increased $7 million, excluding the impact of claims costs related to the change in revenue. Contract claims costs primarily reflects:

    • A higher number of service requests per member, primarily due to approximately $9 million of unfavorable weather in the HVAC trade;

    • Normal cost inflation across our contractor network, replacement parts and equipment, which was largely offset by process improvement initiatives;

    • Favorable claims cost development of $6 million, compared to a $5 million favorable claims cost development in the third-quarter of 2025.

  • $6 million of lower other general and administrative costs due to lower personnel costs.

  • $4 million of higher sales and marketing costs, primarily due to increased marketing investments to drive direct-to-consumer channel growth.

Cash Flow

 

 

Nine Months Ended

 

 

September 30,

(In millions)

 

2026

 

2025

Net cash provided from (used for):

 

 

 

 

 

 

 

 

Operating activities

 

$

 

318

 

 

$

 

315

 

Investing activities

 

 

 

(22

)

 

 

 

37

 

Financing activities

 

 

 

(281

)

 

 

 

(210

)

Cash increase during the period

 

$

 

15

 

 

$

 

142

 

Net cash provided from operating activities was $318 million for the nine months ended September 30, 2026 and was comprised of $393 million in earnings adjusted for non-cash charges, partially offset by $74 million in cash used for working capital.

Net cash used for investing activities was $22 million for the nine months ended September 30, 2026 and was primarily comprised of capital expenditures related to technology projects.

Net cash used for financing activities was $281 million for the nine months ended September 30, 2026 and was primarily comprised of $259 million of share repurchases (excluding taxes and fees) and $22 million of scheduled debt payments.

Free Cash Flow(2) was $298 million for the nine months ended September 30, 2026.

Cash as of September 30, 2026 was $581 million and was comprised of $151 million of restricted net assets and $430 million of Unrestricted Cash.

Capital Allocation

The company expects to complete the existing 3-year, $650 million share repurchase authorization in November 2026, nearly one year ahead of schedule.

Additionally, on October 30, 2026, Frontdoor’s Board of Directors approved a new, 3-year, $1 billion share repurchase authorization, beginning in November 2026.

Fourth-Quarter 2026 Outlook

  • Revenue of $453 million to $463 million.

  • Adjusted EBITDA(5) of $62 million to $72 million.

Full-Year 2026 Outlook

  • Revenue of $2.205 billion to $2.215 billion, approximately a 6% increase over full-year 2025. Key assumptions:

    • Realized price increase of approximately 4%.

    • Volume increase of approximately 2%.

    • Approximately 5% increase in renewal channel revenue.

    • Low-single digit decrease in direct-to-consumer channel revenue.

    • Low-single digit increase in real estate channel revenue.

    • $235 million to $240 million in non-warranty and other revenue.

  • Number of home warranties to increase approximately 1% in 2026.

  • Gross profit margin of approximately 55%.

  • SG&A of $685 million to $695 million.

  • Adjusted EBITDA(5) of $590 million to $600 million, and Adjusted EBITDA margin(5) of approximately 27%.

  • Capital expenditures of approximately $30 million.

  • Annual effective tax rate of approximately 24%.

Third-Quarter 2026 Earnings Conference Call

Frontdoor has scheduled a conference call today, Thursday, November 5, 2026, at 7:30 a.m. Central time (8:30 a.m. Eastern time). During the call, management will discuss the company’s operational performance and financial results for third-quarter 2026 and respond to questions from the investment community. Participants can register for the conference call by clicking https://www.webcaster5.com/Webcast/Page/3067/54607. Once completed, each participant will receive access details via email. Additionally, the conference call will be available via webcast which will include a slide presentation highlighting the company’s results. To participate via webcast and view the presentation, visit https://investors.frontdoorhome.com.

The call will be available for replay for approximately 60 days. To access the replay of this call, please call 877-481-4010 and enter conference passcode 54607 (international participants: 919-882-2331, conference passcode 54607). To view a replay of the webcast, visit https://investors.frontdoorhome.com .

About Frontdoor, Inc.

Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services.

Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings.

Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components.

Frontdoor’s family of brands includes American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW. For more information about Frontdoor, Inc., please visit frontdoorhome.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, projected future performance and any statements about Frontdoor’s plans, strategies and prospects. Forward-looking statements can be identified by the use of forward-looking terms such as “believe,” “expect,” “estimate,” “could,” “should,” “intend,” “may,” “plan,” “seek,” “anticipate,” “project,” “will,” “shall,” “would,” “aim,” or other comparable terms. These forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Such risks and uncertainties include, but are not limited to: changes in macroeconomic conditions, including inflation, tariffs and global supply chain challenges and changing interest rates, especially as they may affect existing or new home sales, consumer confidence, demand for our services, labor availability or our costs; our ability to successfully implement our business strategies; the ability of our marketing efforts to be successful and cost-effective; our dependence on our first-year direct-to-consumer and real estate acquisition channels and our renewal channel for home warranty sales; our dependence on our existing warranty customer base, and strategic partners for non-warranty sales; changes in the source and intensity of competition in our market; our ability to attract, retain and maintain positive relations with third-party contractors and vendors; increases in parts, appliance and home system prices, and other operating costs; changes in U.S. tariffs or import/export regulations; our ability to attract and retain qualified key employees and labor availability in our customer service operations; our dependence on third-party vendors, including business process outsourcers, and third-party component suppliers; weather, including adverse conditions, seasonality, along with related environmental regulations; compliance with, or violation of, laws and regulations, including consumer protection laws, or lawsuits or other claims by third parties, increasing our legal and regulatory expenses; cybersecurity breaches, disruptions or failures in our technology systems; our ability to protect the security of personal information about our customers; technological developments in artificial intelligence; negative reputational and financial impacts resulting from acquisitions or strategic transactions; a requirement to recognize impairment charges on goodwill and intangible assets; our ability to underwrite risks accurately and to charge adequate prices to builder members, as well as our ability to effectively re-insure a large portion of those risks; the availability of reinsurance to manage a substantial portion of our potential loss exposure for our new home builder warranty business; evolving corporate governance and disclosure regulations and expectations; inappropriate use of social media by us or other parties to harm our reputation; our ability to protect our intellectual property and other material proprietary rights; third-party use of our trademarks as search engine keywords to direct our potential customers to their own websites; special risks applicable to operations outside the United States by us or our business process outsource providers; the acquisition of 2-10 Home Buyers Warranty may not achieve its intended results; any liabilities, losses, or other exposures for which we do not have adequate insurance coverage, indemnification, or other protection; a return on investment in our common stock is dependent on appreciation in the price; inclusion in our certificate of incorporation of a forum selection clause that could discourage an acquisition of our company or litigation against us and our directors and officers; the effects of our significant indebtedness, our ability to incur additional debt and the limitations contained in the agreements governing such indebtedness; increases in interest rates increasing the cost of servicing our indebtedness and counterparty credit risk due to instruments designed to minimize exposure to market risks; increased borrowing costs due to lowering or withdrawal of the credit ratings, outlook or watch assigned to us or our Credit Facilities; and our ability to generate the significant amount of cash needed to fund our operations and service our debt obligations. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this news release. For a discussion of other important factors that could cause Frontdoor’s results to differ materially from those expressed in, or implied by, the forward-looking statements included in this document, refer to the risks and uncertainties detailed from time to time in Frontdoor’s periodic reports filed with the SEC, including the disclosure contained in Item 1A. Risk Factors in our 2025 Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in Frontdoor’s periodic filings with the SEC. Except as required by law, Frontdoor does not undertake any obligation to update or revise the forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review Frontdoor’s filings with the SEC, which are available from the SEC’s EDGAR database at sec.gov, and via Frontdoor’s website at frontdoorhome.com.

Non-GAAP Financial Measures

To supplement Frontdoor’s results presented in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), Frontdoor has disclosed the non-GAAP financial measures of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Net Income, Adjusted Diluted Earnings per Share, and Unrestricted Cash.

We define “Adjusted EBITDA” as net income before depreciation and amortization expense; goodwill and intangibles impairment; restructuring charges; acquisition and integration related costs; provision for income taxes; non-cash stock-based compensation expense; interest expense; loss on extinguishment of debt; and other non-operating expenses. We define “Adjusted EBITDA margin” as Adjusted EBITDA divided by revenue. We believe Adjusted EBITDA and Adjusted EBITDA margin are useful for investors, analysts and other interested parties as they facilitate company-to-company operating performance comparisons by excluding potential differences caused by variations in capital structures, taxation, the age and book depreciation of facilities and equipment, restructuring and acquisition initiatives and equity-based, long-term incentive plans.

We define “Free Cash Flow” as net cash provided from operating activities less property additions. Free Cash Flow is not a measurement of our financial performance or liquidity under U.S. GAAP and does not purport to be an alternative to net cash provided from operating activities or any other performance or liquidity measures derived in accordance with U.S. GAAP. Free Cash Flow is useful as a supplemental measure of our liquidity. Management uses Free Cash Flow to facilitate company-to-company cash flow comparisons, which may vary from company-to-company for reasons unrelated to operating performance.

We define “Adjusted Net Income” as net income before: amortization expense; acquisition and integration related costs; restructuring charges; loss on extinguishment of debt; other non-operating expenses; and the tax impact of the aforementioned adjustments. We believe Adjusted Net Income is useful for investors, analysts and other interested parties as it facilitates company-to-company operating performance comparisons by excluding potential differences caused by items listed in this definition.

We define “Adjusted Diluted Earnings per Share” as Adjusted Net Income divided by the weighted-average diluted common shares outstanding.

We define “Unrestricted Cash” as cash not subject to third-party restrictions. For additional information related to our third-party restrictions, see “Liquidity and Capital Resources — Liquidity” under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2025 Annual Report on Form 10-K filed with the SEC.

See the schedules attached hereto for additional information and reconciliations of such non-GAAP financial measures. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of Frontdoor’s business performance and are useful for period-over-period comparisons of the performance of Frontdoor’s business. While we believe that these non-GAAP financial measures are useful in evaluating our business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these non-GAAP financial measures may not be the same as similarly entitled measures reported by other companies.

© 2026 Frontdoor, Inc. All rights reserved. The following terms, which may be used in this press release, are trademarks of Frontdoor, Inc. and its subsidiaries: Frontdoor®, American Home Shield®, HSA™, 2-10 HBW® , OneGuard®, Landmark Home Warranty®, and related logos and designs. All other trademarks used herein are the property of their respective owners.

(1)

All references to earnings per share (EPS) and adjusted earnings per share reflect EPS on a diluted basis.

 

(2)

See “Reconciliations of Non-GAAP Financial Measures” accompanying this release for a reconciliation of Adjusted EBITDA, Free Cash Flow, Adjusted Net Income and Adjusted Diluted Earnings per Share, each a non-GAAP measure, to the nearest GAAP measure. See “Non-GAAP Financial Measures” included in this release for descriptions of calculations of these measures. Amounts presented in the reconciliations and other tables presented herein may not sum due to rounding.

 

(3)

Revenue conversion includes the impact of the change in the number of home warranties as well as the impact of year-over-year price changes. The impact of the change in the number of home warranties considers the associated revenue on those plans less an estimate of contract claims costs based on margin experience in the prior year period.

 

(4)

Contract claims costs includes the impact of changes in service request incidence, inflation and other drivers associated with the number of home warranties in the prior year period. The impact on contract claims costs resulting from year-over-year changes in the number of home warranties is included in revenue conversion above.

 

(5)

A reconciliation of the forward-looking Adjusted EBITDA and Adjusted EBITDA Margin outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Frontdoor, Inc.

Consolidated Statements of Operations and Comprehensive Income (Unaudited)

(In millions, except per share data)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

 

2026

 

2025

 

2026

 

2025

Revenue

 

$

655

 

 

$

618

 

 

$

1,752

 

 

$

1,660

 

Cost of services rendered

 

 

293

 

 

 

264

 

 

 

763

 

 

 

716

 

Gross Profit

 

 

362

 

 

 

353

 

 

 

988

 

 

 

944

 

Selling and administrative expenses

 

 

174

 

 

 

174

 

 

 

512

 

 

 

498

 

Depreciation and amortization expense

 

 

20

 

 

 

22

 

 

 

61

 

 

 

66

 

Restructuring charges

 

 

1

 

 

 

1

 

 

 

3

 

 

 

1

 

Interest expense

 

 

19

 

 

 

20

 

 

 

57

 

 

 

59

 

Interest and net investment income

 

 

(6

)

 

 

(6

)

 

 

(16

)

 

 

(16

)

Income before Income Taxes

 

 

154

 

 

 

142

 

 

 

372

 

 

 

336

 

Provision for income taxes

 

 

38

 

 

 

37

 

 

 

89

 

 

 

83

 

Net Income

 

$

116

 

 

$

106

 

 

$

283

 

 

$

253

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Comprehensive Income (Loss), Net of Income Taxes:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on derivative instruments, net of income taxes

 

 

11

 

 

 

(1

)

 

 

19

 

 

 

(13

)

Total Other Comprehensive Income (Loss), Net of Income Taxes

 

 

11

 

 

 

(1

)

 

 

19

 

 

 

(13

)

Comprehensive Income

 

$

127

 

 

$

105

 

 

$

302

 

 

$

240

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per Share:

​

​

 

​

​

 

​

​

 

 

​

 

Basic

​

$

1.69

 

 

$

1.45

 

 

$

4.06

 

 

$

3.44

 

Diluted

​

$

1.65

 

 

$

1.42

 

 

$

3.97

 

 

$

3.38

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average Common Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

68.7

 

 

 

72.8

 

 

 

69.7

 

 

 

73.6

 

Diluted

 

 

70.3

 

 

 

74.4

 

 

 

71.1

 

 

 

75.0

 

Frontdoor, Inc.

Condensed Consolidated Statements of Financial Position (Unaudited)

(In millions, except share data)

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Assets:

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

581

 

 

$

566

 

Receivables, less allowance of $4 and $4, respectively

 

 

13

 

 

 

10

 

Prepaid expenses and other current assets

 

 

45

 

 

 

44

 

Contract assets

 

 

85

 

 

 

—

 

Assets held for sale

 

 

—

 

 

 

4

 

Total Current Assets

 

 

724

 

 

 

624

 

Other Assets:

 

 

 

 

 

 

Property and equipment, net

 

 

53

 

 

 

57

 

Goodwill

 

 

963

 

 

 

959

 

Intangible assets, net

 

 

362

 

 

 

398

 

Operating lease right-of-use assets

 

 

6

 

 

 

7

 

Deferred reinsurance

 

 

67

 

 

 

66

 

Deferred customer acquisition costs

 

 

15

 

 

 

14

 

Other assets

 

 

33

 

 

 

17

 

Total Assets

 

$

2,223

 

 

$

2,142

 

Liabilities and Shareholders’ Equity:

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable

 

$

102

 

 

$

89

 

Accrued liabilities:

 

 

 

 

 

 

Payroll and related expenses

 

 

30

 

 

 

47

 

Home warranty claims

 

 

76

 

 

 

69

 

Income taxes payable

 

 

42

 

 

 

26

 

Other

 

 

34

 

 

 

34

 

Deferred revenue

 

 

101

 

 

 

107

 

Current portion of long-term debt

 

 

29

 

 

 

29

 

Total Current Liabilities

 

 

414

 

 

 

402

 

Long-Term Debt

 

 

1,125

 

 

 

1,144

 

Other Long-Term Liabilities:

 

 

 

 

 

 

Deferred tax liabilities, net

 

 

81

 

 

 

53

 

Operating lease liabilities

 

 

16

 

 

 

18

 

Unearned insurance premium

 

 

238

 

 

 

236

 

Long-term deferred revenue

 

 

16

 

 

 

19

 

Other long-term liabilities

 

 

18

 

 

 

27

 

Total Other Long-Term Liabilities

 

 

369

 

 

 

354

 

Commitments and Contingencies

 

 

 

 

 

 

Shareholders’ Equity:

 

 

 

 

 

 

Common stock, $0.01 par value; 2,000,000,000 shares authorized; 89,330,812 shares issued and 68,082,707 shares outstanding as of September 30, 2026 and 88,480,560 shares issued and 70,958,215 shares outstanding as of December 31, 2025

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

228

 

 

 

195

 

Retained earnings

 

 

1,068

 

 

 

785

 

Accumulated other comprehensive income (loss)

 

 

7

 

 

 

(12

)

Less treasury stock, at cost; 21,248,105 shares as of September 30, 2026 and 17,522,345 shares as of December 31, 2025

 

 

(988

)

 

 

(727

)

Total Shareholders’ Equity

 

 

315

 

 

 

242

 

Total Liabilities and Shareholders’ Equity

 

$

2,223

 

 

$

2,142

 

Frontdoor, Inc.

Consolidated Statements of Cash Flows (Unaudited)

(In millions)

 

 

 

Nine Months Ended

 

 

September 30,

 

 

2026

 

2025

Cash and Cash Equivalents at Beginning of Period

 

$

566

 

 

$

421

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

Net Income

 

 

283

 

 

 

253

 

Adjustments to reconcile net income to net cash provided from operating activities:

 

 

 

 

 

 

Depreciation and amortization expense

 

 

61

 

 

 

66

 

Deferred income tax expense

 

 

21

 

 

 

10

 

Stock-based compensation expense

 

 

31

 

 

 

25

 

Other

 

 

(2

)

 

 

1

 

Changes in:

 

 

 

 

 

 

Receivables

 

 

(2

)

 

 

—

 

Prepaid expenses and other current assets

 

 

(88

)

 

 

(79

)

Deferred reinsurance

 

 

(1

)

 

 

(4

)

Deferred customer acquisition costs

 

 

(2

)

 

 

(2

)

Accounts payable

 

 

13

 

 

 

33

 

Deferred revenue

 

 

(9

)

 

 

(21

)

Accrued liabilities

 

 

(7

)

 

 

(12

)

Deferred insurance premiums

 

 

1

 

 

 

7

 

Current income taxes

 

 

21

 

 

 

37

 

Net Cash Provided from Operating Activities

 

 

318

 

 

 

315

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(20

)

 

 

(20

)

Business acquisitions, net of cash acquired

 

 

—

 

 

 

3

 

Purchases of short-term investments and available-for-sale securities

 

 

(2

)

 

 

(6

)

Sales and maturities of available-for-sale securities

 

 

—

 

 

 

60

 

Net Cash (Used for) Provided from Investing Activities

 

 

(22

)

 

 

37

 

Cash Flows from Financing Activities:

 

 

 

 

 

 

Repayments of debt

 

 

(22

)

 

 

(22

)

Repurchases of common stock

 

 

(261

)

 

 

(195

)

Other financing activities

 

 

2

 

 

 

7

 

Net Cash Used for Financing Activities

 

 

(281

)

 

 

(210

)

Cash Increase During the Period

 

 

15

 

 

 

142

 

Cash and Cash Equivalents at End of Period

 

$

581

 

 

$

563

 

Reconciliations of Non-GAAP Financial Measures

 

The following table presents reconciliations of Net Income to Adjusted Net Income.

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(In millions, except per share amounts)

 

2026

 

2025

 

2026

 

2025

Net Income

 

$

116

 

 

$

106

 

 

$

283

 

 

$

253

 

Amortization expense

 

 

12

 

 

 

13

 

 

 

37

 

 

 

38

 

Acquisition and integration related costs

 

 

2

 

 

 

2

 

 

 

5

 

 

 

6

 

Restructuring Charges

 

 

1

 

 

 

1

 

 

 

3

 

 

 

1

 

Tax Impact of Adjustments

 

 

(3

)

 

 

(3

)

 

 

(10

)

 

 

(10

)

Adjusted Net Income

 

$

127

 

 

$

117

 

 

$

318

 

 

$

288

 

Adjusted Earnings per Share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.85

 

 

$

1.61

 

 

$

4.56

 

 

$

3.91

 

Diluted

 

$

1.81

 

 

$

1.58

 

 

$

4.47

 

 

$

3.84

 

Weighted-average Common Shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

68.7

 

 

 

72.8

 

 

 

69.7

 

 

 

73.6

 

Diluted

 

 

70.3

 

 

 

74.4

 

 

 

71.1

 

 

 

75.0

 

The following table presents reconciliations of net cash provided from operating activities to Free Cash Flow.

 

 

 

Nine Months Ended

 

 

September 30,

(In millions)

 

2026

 

2025

Net cash provided from operating activities

 

$

318

 

 

$

315

 

Property additions

 

 

(20

)

 

 

(20

)

Free Cash Flow

 

$

298

 

 

$

296

 

The following table presents reconciliations of Net Income to Adjusted EBITDA.

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

(In millions)

 

2026

 

2025

 

2026

 

2025

 

Net Income

 

$

116

 

$

106

 

$

283

 

$

253

 

Depreciation and amortization expense

 

 

20

 

 

22

 

 

61

 

 

66

 

Restructuring charges

 

 

1

 

 

1

 

 

3

 

 

1

 

Acquisition and integration related costs

 

 

2

 

 

2

 

 

5

 

 

6

 

Provision for income taxes

 

 

38

 

 

37

 

 

89

 

 

83

 

Non-cash stock-based compensation expense

 

 

9

 

 

8

 

 

31

 

 

25

 

Interest expense

 

 

19

 

 

20

 

 

57

 

 

59

 

Other non-operating expenses

 

 

—

 

 

—

 

 

—

 

 

1

 

Adjusted EBITDA

 

$

205

 

$

195

 

$

528

 

$

494

 

Key Business Metrics

 

 

 

As of September 30,

 

 

 

2026

 

2025

 

Number of home warranties (in millions)

 

 

2.14

 

 

 

2.11

 

 

Renewals

 

 

1.59

 

 

 

1.58

 

 

First-Year Direct-To-Consumer

 

 

0.33

 

 

 

0.32

 

 

First-Year Real Estate

 

 

0.22

 

 

 

0.21

 

 

Increase (Reduction) in number of home warranties(1)

 

 

1

 

%

 

8

 

%

Customer retention rate

 

 

79.7

 

%

 

79.4

 

%

(1)

As of September 30, 2025, excluding the 2-10 HBW home warranties acquired on December 19, 2024, the reduction in home warranties was 1 percent.

FTDR-Financial

For further information, contact:

Investor Relations:

Matt Davis

901.701.5199

[email protected]

Media:

Alison Bishop

901.701.5198

[email protected]

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: HVAC Residential Building & Real Estate Manufacturing Commercial Building & Real Estate Construction & Property Building Systems

MEDIA:

Logo
Logo

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key 
pathogenic drivers
of
atherosclerotic cardiovascular disease (ASCVD)
to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates comparable to placebo; Phase 2 initiation in coronary artery disease anticipated in H1 2027

Initiation of Phase 2 study of MRT-8102 in gout expected in Q4 2026, with data update expected in H2 2027; additional Phase 2 initiation in hidradenitis suppurativa anticipated in H1 2027

Initiated MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations; Phase 2 data update expected in 2027; updated Phase 1/2 study data expected this year

Novartis initiated Phase 2a/b studies of VAV1-directed MGD MRT-6160 (DDY391) in Sjögren’s disease and psoriatic arthritis, triggering a total of $87.5 million in Phase 2 milestone payments to date to Monte Rosa

Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $582.6 million (not including MRT-6160 Phase 2 initiation milestones) as of September 30, 2026, expected to support operations into 2029

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced business highlights and financial results for the third quarter ended September 30, 2026.

“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “The GFORCE-1 results reinforce our view that targeting NEK7 at the top of the NLRP3 signaling cascade could address a broader set of disease drivers than targeting individual downstream cytokines. Our planned Phase 2 studies in coronary artery disease (CAD), gout, and hidradenitis suppurativa, conditions with major unmet needs, are intended to deepen our understanding of the therapeutic potential of NEK7 degradation. In CAD, our innovative study design integrates molecular and imaging-based readouts to explore how MRT-8102’s broad biological activity translates into changes in coronary plaque biology, to inform patient selection and design for an efficient future Phase 3 study.” 

Dr. Warmuth continued: “We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use. With the emergence of next-generation urate-lowering drugs and their propensity to induce flares in the first 6 to 12 months of use, we believe the need for a well-tolerated, non-immunosuppressive flare prevention treatment will only increase. We expect initial data from our Phase 2 gout study in H2 2027. Across the broader pipeline, we are pursuing a focused development strategy for MRT-2359 through MODeFIRe-1, evaluating its potential in combination with apalutamide in mCRPC patients with AR mutations. We have shown previously that degradation of GSPT1 dampens MYC signaling in CRPC, a pathway we believe is moving to center stage for new treatment options in CRPC. We look forward to a data update from this Phase 2 study in 2027, as well as a final data update from our completed Phase 1/2 study of MRT-2359 in combination with enzalutamide by year-end. Novartis’s advancement of MRT-6160 (DDY391) into Phase 2 studies in Sjögren’s disease and psoriatic arthritis expands the evaluation of VAV1 degradation across immune-mediated diseases and brings additional non-dilutive funding to Monte Rosa. With our balance sheet expected to support operations into 2029, we are well positioned to pursue these opportunities while maintaining a disciplined focus on generating clinical evidence and advancing our pipeline.”

RECENT HIGHLIGHTS

MRT-8102, NEK7-directed MGD for inflammatory diseases driven by NEK7/NLRP3 and IL-1

  • In October, Monte Rosa reported positive results from GFORCE-1 (NCT07119125), a Phase 1 study of MRT-8102 in 108 obese subjects with elevated cardiovascular disease risk. Across all three dose levels, MRT-8102 achieved median NEK7 degradation of approximately 80% to 90%. MRT-8102 also resulted in substantial reductions of IL-1β as well as HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to pathogenic biology within atherosclerotic plaques and vessel walls. MRT-8102 was well tolerated, with no serious adverse events, adverse event rates similar to placebo, and no evidence of increased infection risk.
  • With dose selection informed by the GFORCE-1 data, Monte Rosa plans to initiate three Phase 2 studies of MRT-8102:
    • GEMINI-1, a Phase 2 study in patients with gout, is expected to initiate in Q4 2026. The study will evaluate prevention of flare recurrence following management of acute flares, with initial data expected in H2 2027.
    • GFORCE-2, a focused Phase 2b study in patients with stable coronary artery disease and residual inflammation, is expected to initiate in H1 2027. The study is expected to evaluate imaging-based coronary artery plaque assessment, such as fat attenuation index (FAI), along with NLRP3 genetics and molecular drivers of local disease pathogenesis and systemic inflammation, to inform the design of an innovative and efficient Phase 3 study focused on the most disease-modifiable patient population.
    • GALAXY-1, a Phase 2 study in patients with moderate to severe hidradenitis suppurativa, is expected to initiate in H1 2027.
  • Due to prioritization of the MRT-8102 Phase 2 study initiations, Investigational New Drug (IND) submission for the next-generation NEK7 MGD is now anticipated in 2027.

MRT-2359, GSPT1-directed MGD for mCRPC

  • In August, Monte Rosa dosed the first patient in MODeFIRe-1 (NCT07745361), a Phase 2 study of MRT-2359 in combination with apalutamide in AR-mutant mCRPC patients who received prior treatment with a second-generation AR inhibitor. The study will enroll up to 25 patients, with MRT-2359 administered orally at 0.5 mg on a 21 days on, 7 days off schedule. Endpoints include PSA response, RECIST response, duration of response, radiographic progression-free survival, PSA progression-free survival, and safety. Monte Rosa has a clinical supply agreement with Johnson & Johnson to support the study.
  • Enrollment in the initial Phase 1/2 study expansion arm, in patients with mCRPC, has been completed. A total of 6 patients with AR mutations were enrolled and treated with MRT-2359 in combination with enzalutamide. Monte Rosa plans to provide an update on this patient subset by the end of the year. Interim data were presented at the ASCO Genitourinary Cancers Symposium (ASCO GU) in February.

MRT-6160 (DDY391), VAV1-directed MGD for immune-mediated conditions

  • In September, Monte Rosa announced achievement of a milestone associated with its collaborator Novartis initiating a global Phase 2a/b randomized, double-blind, placebo-controlled study (NCT07737743), evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY391) in participants with Sjögren’s disease. The first patient visit triggered a $50 million milestone payment to Monte Rosa.
  • In October, Monte Rosa announced achievement of an additional milestone associated with Novartis initiating a second Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis (PsA). The Phase 2a/b randomized, double-blind, placebo-controlled, multicenter study (NCT07801495) will evaluate the efficacy, safety, tolerability, and dose-response relationship of MRT-6160 (DDY391). The first patient visit triggered a $37.5 million milestone payment to Monte Rosa.
  • The Sjögren’s and PsA studies are the first two of several studies expected for MRT-6160 (DDY391). Under its global exclusive development and commercialization license agreement with Novartis, Monte Rosa is eligible for additional Phase 2 study initiation milestone payments.

CDK2 and Cyclin E1-directed MGD programs for solid tumors

  • Monte Rosa expects to submit IND applications for its CDK2 and cyclin E1 (CCNE1)-directed MGD programs in 2027.

ANTICIPATED UPCOMING MILESTONES AND DEVELOPMENT PRIORITIES

Immunology and inflammation programs

  • Initiate GEMINI-1 Phase 2 study of MRT-8102 in gout in Q4 2026, with initial data expected in H2 2027.
  • Initiate GFORCE-2 Phase 2b study of MRT-8102 in stable coronary artery disease in H1 2027.
  • Initiate GALAXY-1 Phase 2 study of MRT-8102 in moderate to severe hidradenitis suppurativa in H1 2027.
  • Monte Rosa expects its collaborator, Novartis, to initiate additional Phase 2 studies of MRT-6160 (DDY391) in immune-mediated diseases.

Oncology programs

  • Provide a clinical data update on the initial Phase 1/2 expansion arm exploring MRT-2359 in combination with enzalutamide in mCRPC by the end of 2026.
  • Provide a clinical data update on the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations in 2027.
  • Submit an IND application for a CDK2-directed MGD in 2027.
  • Submit an IND application for a CCNE1-directed MGD in 2027.

THIRD QUARTER 2026 FINANCIAL RESULTS

Collaboration Revenue: Collaboration revenue for the third quarter of 2026 was $54.4 million, compared to $12.8 million for the third quarter of 2025. The increase was primarily driven by recognition of collaboration revenue from the $50.0 million milestone triggered by the initiation of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with Sjögren’s disease. The $37.5 million milestone triggered by the initiation of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with psoriatic arthritis in October is not reflected in third quarter collaboration revenue as it was triggered after the end of the quarter. Collaboration revenue represents amounts earned from Monte Rosa’s collaboration and license agreements with Roche and Novartis.

Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were $45.4 million, compared to $36.7 million for the third quarter of 2025. The increase was primarily driven by increased spending on development and discovery programs. R&D expenses included non-cash stock-based compensation of $3.3 million for the third quarter of 2026, compared to $2.5 million in the same period in 2025.

General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were $10.9 million, compared to $9.1 million for the third quarter of 2025. G&A expenses included non-cash stock-based compensation of $3.0 million for the third quarter of 2026, compared to $1.9 million in the same period in 2025.

Net Income (Loss): Net income for the third quarter of 2026 was $3.1 million, compared to a net loss of $27.1 million for the third quarter of 2025.

Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, were $582.6 million, compared to $626.0 million as of June 30, 2026. The decrease of $43.4 million was primarily due to operational use of cash. In September, Monte Rosa announced achievement of a $50 million milestone associated with the first patient visit of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with Sjögren’s disease. In October, Monte Rosa announced achievement of a $37.5 million milestone associated with the first patient visit of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis. Cash receipts from these milestones are not reflected in the September 30th cash balance as the payments had not yet been received as of that date. Monte Rosa expects that its cash, cash equivalents, restricted cash, and marketable securities will support operations into 2029.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Forward-Looking Statements

This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our ability to grow our product pipeline, our ability to successfully complete research and further development and commercialization of our drug candidates in current or future indications, including the timing and results of our clinical trials and our ability to conduct and complete clinical trials, statements regarding our progress and speed of development of only-in-class and first-in-class molecular glue degrader therapeutics, statements about our QuEEN™ discovery engine and the broad potential applications of the platform and our ability to create long-term value through focused pipeline execution and strategic collaborations, as well as to expand the targetable protein space for MGD drug discovery, statements about our potential to rationally design MGDs with unprecedented selectivity, statements about the advancement and timeline of our preclinical and clinical programs, pipeline and the various products therein, including (i) the ongoing development of our VAV1-directed degrader, referred to as MRT-6160 (DDY391), including the initiation of Phase 2 clinical studies in Sjögren’s disease and psoriatic arthritis by our collaborator Novartis, our expectations regarding the milestone payments triggered by the initiation of such Phase 2 studies, additional Phase 2 study activations expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases, our eligibility for additional Phase 2 study initiation milestone payments, (ii) the ongoing development of our NEK7-directed MGD, referred to as MRT-8102, including the positive results from the GFORCE-1 Phase 1 study and the clinical significance of the data observed, statements regarding the potential of MRT-8102 to normalize local and systemic pathologic drivers of ASCVD and to provide differentiated clinical impact across NEK7/NLRP3-driven inflammatory diseases, including compared with targeting individual downstream cytokines, our expectations to initiate multiple Phase 2 studies of MRT-8102, including the GEMINI-1 study in gout patients in Q4 2026 with initial data expected in H2 2027, the GFORCE-2 Phase 2b study in patients with stable coronary artery disease and residual inflammation in H1 2027, including use of coronary artery imaging, NLRP3 genetics and biomarkers to identify a disease-modifiable patient population and inform the design of a potential Phase 3 study, and the GALAXY-1 study in moderate to severe hidradenitis suppurativa patients in H1 2027, statements regarding dose selection informed by GFORCE-1 data for further development across various NLRP3-driven diseases, statements regarding the potential of MRT-8102 in gout, (iii) the ongoing development of a next-generation NEK7-directed MGD and expected IND submission in 2027, (iv) our ongoing clinical development of MRT-2359, including the initiation of the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations, with potential to expand the study into additional patient subsets, our plans to provide updated data from the initial Phase 1/2 study expansion arm in patients with metastatic CRPC by the end of the year, statements regarding the clinical significance of the data observed and the potential of MRT-2359 to benefit patients with mCRPC with AR mutations, and our clinical supply agreement with Johnson & Johnson to support such trial, and (v) progress of our CDK2 and cyclin E1-directed MGD programs, including the timing of IND application submissions in 2027 for CDK2-directed and cyclin E1-directed MGDs, as well as statements related to the expected potential clinical benefit of any of our candidates, advancement and application of our platform, our ability to capitalize on and potential benefits resulting from our research and translational insights, including announcements related to preclinical programs, as well as our ability to optimize collaborations with industry partners, statements about obligations under our collaboration agreements, expectations around the receipt of payments under such agreements and the future development and commercialization of various products, statements regarding regulatory filings, including the planned timing of such filings, and potential review by regulatory authorities, our use of capital, expenses and other financial results in the future, ability to fund operations and capital expenditures into 2029, as well as our expectations of success for our programs, strength of collaboration relationships and the strength of our financial position, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on March 17, 2026, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, as well as the risk that outcomes of preclinical studies may not be predictive of clinical trial results and the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)
(unaudited)
    September 30,     December 31,  
      2026       2025  
Assets            
Current assets:            
Cash and cash equivalents   $ 45,180     $ 129,883  
Marketable securities     532,546       247,221  
Collaboration receivable     50,000       7,000  
Other receivables     7,624       4,600  
Prepaid expenses and other current assets     4,715       4,481  
Total current assets     640,065       393,185  
Property and equipment, net     28,632       25,986  
Operating lease right-of-use assets     23,343       24,386  
Restricted cash     4,918       4,954  
Other long-term assets     767       148  
Total assets   $ 697,725     $ 448,659  
Liabilities and stockholders’ equity                
Current liabilities:            
Accounts payable   $ 3,347     $ 3,550  
Accrued expenses and other current liabilities     33,414       26,694  
Current deferred revenue     21,098       29,571  
Current portion of operating lease liability     4,187       4,397  
Total current liabilities     62,046       64,212  
Deferred revenue, net of current     102,261       111,332  
Defined benefit plan liability     5,131       5,265  
Operating lease liability, net of current     32,079       34,794  
Total liabilities     201,517       215,603  
Stockholders’ equity            
Common stock, $0.0001 par value; 500,000,000 shares authorized, 85,431,211 and 65,543,723 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     9       7  
Additional paid-in capital     1,064,442       714,090  
Accumulated other comprehensive loss     (6,192 )     (3,827 )
Accumulated deficit     (562,051 )     (477,214 )
Total stockholders’ equity     496,208       233,056  
Total liabilities and stockholders’ equity   $ 697,725     $ 448,659  

Consolidated Statements of Income (Loss)

(in thousands)


(unaudited)
    Three months ended

September 30,
    Nine months ended

September 30,
 
    2026     2025     2026     2025  
Collaboration revenue   $ 54,366     $ 12,768     $ 67,544     $ 120,891  
Operating expenses:                        
Research and development     45,363       36,678       137,396       99,521  
General and administrative     10,942       9,065       31,251       25,863  
Total operating expenses     56,305       45,743       168,647       125,384  
Loss from operations     (1,939 )     (32,975 )     (101,103 )     (4,493 )
Other income:                        
Interest income     5,625       2,746       17,132       9,253  
Foreign currency exchange gain (loss)     93       (29 )     110       1,534  
Gain on disposal of property and equipment     —       —       —       59  
Total other income     5,718       2,717       17,242       10,846  
Net income (loss) before income taxes   $ 3,779     $ (30,258 )   $ (83,861 )   $ 6,353  
Income tax (provision) benefit     (716 )     3,177       (976 )     1,156  
Net income (loss)   $ 3,063     $ (27,081 )   $ (84,837 )   $ 7,509  



Investors


Andrew Funderburk
[email protected]

Media

Cory Tromblee, Scient PR
[email protected]



TiC Solutions Reports Results for the Third Quarter 2026

TiC Solutions Reports Results for the Third Quarter 2026

– Delivered record third quarter revenue of $639.6 million, up 35%, or up12.5%on a combined basis –

– Reported net loss of $11.1 million and Adjusted EBITDA of $107.2 million –

– Achieved record combined Consulting & Engineering and Geospatial backlog of $1.29 billion, up 23% YoY –

– Increases full-year 2026 revenue outlook –

HOUSTON–(BUSINESS WIRE)–
TIC Solutions, Inc. (NYSE: TIC) (“TiC Solutions” or the “Company”), a leading provider of tech-enabled asset integrity, engineering, and geospatial services, today reported its financial results for the three and nine months ended September 30, 2026.

The Company’s third quarter 2026 results include the financial performance of NV5 Global, Inc. (“NV5”) for the period following our acquisition of NV5 on August 4, 2025 (the “NV5 Acquisition”). All periods prior to August 4, 2025 reflect legacy Acuren results only and therefore exclude any contribution from NV5 which materially affected year-over-year comparability of our financial results for the periods presented.

Ben Heraud, CEO of TiC Solutions, stated: “We delivered a record third quarter. On a combined basis, revenue grew 12.5%, including organic growth of 8.4%, Adjusted EBITDA grew 19%, and Adjusted EBITDA margin expanded approximately 90 basis points to 16.8%. Revenue increased across all 3 segments. These results reflect progress on our priorities: winning in essential, high-demand end markets and geographies, expanding our role across the asset lifecycle and client relationships, and improving profitability as we scale.

“Investment in aging infrastructure, energy, data centers, and digitization continues to support demand for our services. Cross-selling is contributing to organic growth as our teams combine inspection, engineering, and geospatial capabilities to support clients across the asset lifecycle. Our recent acquisitions add complementary capabilities and client relationships, while record backlog provides visibility heading into 2027. We are increasing our full-year revenue outlook and narrowing our Adjusted EBITDA guidance range, while remaining focused on converting demand into profitable growth and stronger cash flow.”

Third Quarter 2026 Highlights

  • Third quarter 2026 revenue was $639.6 million, compared to thirdquarter 2025 revenue of $473.9 million, representing an increase of 35%, primarily reflecting the inclusion of NV5 results.

  • On a combined basis, revenue increased 12.5% year-over-year in the quarter, including 8.4% organic growth.

  • Third quarter 2026 net loss of $11.1 million compared to third quarter 2025 net loss of $13.9 million.

  • Third quarter 2026 diluted loss per share was $(0.05). Adjusted diluted EPS was $0.18.

  • Third quarter 2026 Adjusted EBITDA of $107.2 million, compared to third quarter 2025 Adjusted EBITDA of $77.3 million, an increase of 39% year-over-year, primarily reflecting the inclusion of NV5 results.

  • As of September 30, 2026, the Company had total liquidity of $293.3 million, including cash and cash equivalents of $197.9 million plus undrawn capacity on the Company’s $125.0 million revolving credit facility. Total term loan debt was $1.6 billion, net of unamortized debt issuance costs at quarter end.

Robert A.E. Franklin, Executive Chairman of TiC Solutions, commented: “This quarter’s results reinforce the strategic rationale of bringing Acuren and NV5 together. Our recent acquisitions add complementary capabilities and client relationships that broaden our growth opportunities in strategic end markets, service lines, and geographies.

“Our priority is to translate that growth into sustained earnings, stronger cash generation, and long-term shareholder value. We will remain disciplined in allocating capital to organic investment and acquisitions while strengthening our balance sheet. We aim to sustain this momentum while improving cash conversion and reducing net leverage as we pursue our 3 / 18 / 85 financial objectives for 2029.”

Fiscal Year 2026 Financial Outlook

TiC Solutions is updating its full-year 2026 guidance to:

  • Revenue of $2,240 to $2,270 million

  • Adjusted EBITDA of $342 to $350 million

Conference Call and Webcast

TiC Solutions will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, November 5, 2026. Participants on the call will include Ben Heraud, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Executive Chairman.

To listen to the call by telephone, please dial 800-343-4136 or 203-518-9843 and reference conference ID “TIC”. You may also attend and view the presentation (live or by replay) via webcast by accessing the following URL:

https://viavid.webcasts.com/starthere.jsp?ei=1779631&tp_key=a4b1b67f83

A replay of the call will be available shortly after the completion of the live call and webcast via the webcast link above.

About TiC Solutions

TiC Solutions is a leading provider of tech-enabled asset integrity, engineering, and geospatial services. The Company delivers mission-critical services across the full lifecycle of industrial assets, buildings, and public infrastructure, from planning and construction through operations and ongoing maintenance. Operating across North America and select international markets, TiC Solutions serves a diversified client base across its principal end markets: oil and gas, industrials, buildings, power and utilities, infrastructure, natural resources, and aerospace and defense. The Company serves federal, state, and municipal customers across public-sector applications and has exposure to data centers and other high-growth industries.

TiC Solutions operates through three reportable segments: Inspection & Mitigation; Consulting & Engineering; and Geospatial, providing asset integrity services, engineering and advisory solutions, and data-driven asset intelligence capabilities. The Company’s services are frequently non-discretionary, compliance-driven, and typically recurring in nature, delivered by more than 12,000 professionals across over 250 locations.

For more information, please visit www.ticsolutions.com.

Forward-Looking Statements

Certain statements in this press release, and on our conference call, are “forward-looking” statements based on assumptions currently believed to be valid. Forward-looking statements are all statements other than statements of historical facts. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “likely,” “plan,” “positioned,” “strategy,” and similar expressions or other words of similar meaning, and the negatives thereof, are intended to identify forward-looking statements. Specific forward-looking statements in this press release include statements regarding the Company’s expectations and beliefs regarding (i) its guidance for revenue and Adjusted EBITDA for the full year 2026, and the assumptions underlying such guidance, (ii) the integration of the NV5 business and other acquired businesses and the anticipated benefits and cost synergies of the combined platform, including realized savings, cross-selling opportunities and momentum, (iii) its ability to improve profitability, drive operating efficiencies, expand margins, generate stronger cash flow, and deleverage over time, (iv) its strategic priorities, including its 2029 objectives for revenue, Adjusted EBITDA margin and free cash flow conversion, (v) its ability to deliver sustainable value creation for its shareholders and gain market share, (vi) its capital allocation strategy, including with respect to acquisitions and stock repurchases, (vii) customer demand and end-market conditions, including investment in infrastructure, energy, data centers, and digitization, (viii) backlog and its conversion into revenue, (ix) net cash interest expense, cash taxes, and capital expenditures for the full year 2026, (x) 2027 performance, including with respect to revenue growth and Adjusted EBITDA growth, and (xi) the growth and performance of its three reportable segments, including the key growth drivers and commercial indicators for Inspection & Mitigation, Consulting & Engineering, and Geospatial. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, (i) economic conditions affecting the industries the Company serves, including the construction industry and the energy sector, as well as general economic conditions; (ii) the ability and willingness of customers to invest in infrastructure projects; (iii) a decline in demand for the Company’s services or for the products and services of its customers; (iv) the fact that the Company’s revenues are derived primarily from contracts with durations of less than six months and the risk that customers will not renew or enter into new contracts; (v) the Company’s ability to successfully acquire other businesses, successfully integrate acquired businesses into its operations and manage the risks and potential liabilities associated with those acquisitions; (vi) the Company’s ability to compete successfully in the industries and markets it serves; (vii) the Company’s ability to properly manage and accurately estimate costs associated with specific customer projects, in particular for arrangements with fixed price terms; (viii) increases in the cost, or reductions in the supply, of the materials used in the Company’s business and for which we bear the risk of such increases; (ix) the inherently dangerous nature of the Company’s services and the risks of potential liability; (x) the seasonality of the Company’s business and the impact of weather conditions; (xi) the Company’s ability to remediate any material weaknesses; (xii) the impact of health, safety and environmental laws and regulations, and the costs associated with compliance with such laws and regulations; (xiii) the Company’s substantial level of indebtedness and the effect of restrictions on its operations set forth in the documents that govern such indebtedness, (xiv) the Company may fail to realize anticipated synergies or other benefits expected from the merger with NV5 in the timeframe expected or at all, (xv) a government shutdown, and (xvi) the ultimate timing, outcome, and results of integrating the operations of Acuren and NV5. For a detailed discussion of cautionary statements and risks that may affect the Company’s future results of operations and financial results, please refer to the Company’s filings with the SEC, including, but not limited to, the risk factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 which was filed with the SEC on March 12, 2026, and any amendments thereto, and in the Company’s quarterly reports on Form 10-Q, each as supplemented or amended from time to time. Forward-looking statements included in this press release speak only as of the date hereof and, except as required by applicable law, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this press release.

All forward-looking statements speak only as of the date they are made and are based on information available at that time. The Company assumes no obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements.

Non-GAAP Financial Measures

This press release and our earnings conference call contain Adjusted Gross Profit, Adjusted Gross Margin, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Organic Change in Revenue (On an NV5 Combined Basis), Combined Revenue Growth, Combined Revenue Growth (Constant Currency), Adjusted Selling, General and Administrative (“SG&A”) Expenses, and Adjusted Earnings Per Diluted Share (“Adjusted EPS”), which are non-U.S. GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission.

As used in this press release, Adjusted Gross Profit is defined as Gross Profit excluding depreciation expense included in cost of revenue for the periods presented. Adjusted Gross Margin is defined as Adjusted Gross Profit divided by revenue. EBITDA is defined as earnings before interest, taxes, depreciation and amortization for the periods presented and Adjusted EBITDA is defined as EBITDA excluding the impact of certain non-cash and other specifically identified items for the periods presented. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by revenue. Organic Change in Revenue provides a consistent basis for year-over-year comparison as it excludes the impacts of material acquisitions, divestitures, and foreign currency translation. When presented on a combined basis, it also reflects the impact of the NV5 acquisition as if it had been owned for the full comparative periods. Adjusted SG&A is defined as SG&A Expense less depreciation and amortization and the impact of certain non-cash and other specifically identified items for the periods presented.

The presentation of Combined Revenue Growth and Combined Revenue Growth (Constant Currency) for the three and nine months ended September 30, 2026 are not in accordance with GAAP or Article 11 of Regulation S-X and consists of the mathematical addition of Legacy Acuren revenue and NV5 revenue for the three and nine months ended September 30, 2025. Combined revenue for the 2025 periods consists of reported Company revenue plus NV5 revenue for the portion of each period prior to the NV5 Acquisition on August 4, 2025. No other adjustments are made to the combined presentation. However, we believe that for purposes of discussion and analysis, the combined financial information is useful for management and investors to assess our ongoing financial and operational performance and trends. Combined Revenue Growth (Constant Currency) is calculated as the difference between reported revenue and revenue at fixed currencies for the period.

The presentation of Adjusted EPS is not in accordance with GAAP. Adjusted EPS reflects adjustments to reported diluted earnings per share (“GAAP EPS”) to eliminate amortization expense of intangible assets from acquisitions, non-cash stock compensation expense, acquisition and integration related expenses, business transformation costs, and other non-recurring charges, net of tax benefits. As we continue our acquisition strategy, the growth in Adjusted EPS may increase at a greater rate than GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS is provided at the end of this news release.

The Company uses these non-GAAP financial measures and additional financial information both in explaining its results to shareholders and the investment community and in its internal evaluation and management of its businesses. The Company’s management believes that these non-GAAP financial measures and the information they provide are useful to investors since these measures (a) permit investors to view the Company’s performance using the same tools that management uses to evaluate the Company’s past performance, reportable business segments and prospects for future performance, (b) permit investors to compare the Company with its peers, (c) determines certain elements of management’s incentive compensation, and (d) provide consistent period-to-period comparisons of the results.

While the Company believes these non-GAAP measures are useful in evaluating the Company’s performance, this information should be considered as supplemental in nature and not as a substitute for or superior to the related financial information prepared in accordance with GAAP. Additionally, these non-GAAP financial measures may differ from similar measures presented by other companies. A reconciliation of these non-GAAP financial measures is included later in this press release.

A reconciliation is not provided for 2026 Adjusted EBITDA guidance range as we are unable to predict the amounts to be adjusted, such as the GAAP tax provision and depreciation. Accordingly, we would not be able to make a detailed reconciliation of Adjusted EBITDA without unreasonable efforts due to our inability to predict the amount and timing of these future items.

 

TIC Solutions, Inc.

Condensed Consolidated Statements of Operations

(amounts in thousands, except share and per share data)

(Unaudited)

 

 

Three Months Ended

 

Nine Months Ended

 

September 30,

2026

 

September 30,

2025

 

September 30,

2026

 

September 30,

2025

Revenue

$

639,620

 

 

$

473,888

 

 

$

1,711,995

 

 

$

1,022,028

 

Cost of revenue

 

413,291

 

 

 

321,161

 

 

 

1,120,207

 

 

 

751,531

 

Gross profit

 

226,329

 

 

 

152,727

 

 

 

591,788

 

 

 

270,497

 

Selling, general and administrative expenses

 

210,337

 

 

 

159,240

 

 

 

594,016

 

 

 

268,099

 

Income (loss) from operations

 

15,992

 

 

 

(6,513

)

 

 

(2,228

)

 

 

2,398

 

Interest expense, net

 

29,251

 

 

 

26,521

 

 

 

86,637

 

 

 

57,979

 

Other income, net

 

(998

)

 

 

(2,585

)

 

 

(2,020

)

 

 

(4,481

)

Loss before income tax benefit

 

(12,261

)

 

 

(30,449

)

 

 

(86,845

)

 

 

(51,100

)

Income tax benefit

 

(1,149

)

 

 

(16,559

)

 

 

(20,842

)

 

 

(11,184

)

Net loss

 

(11,112

)

 

 

(13,890

)

 

 

(66,003

)

 

 

(39,916

)

Undistributed loss allocated to Series A Preferred Stock

 

51

 

 

 

82

 

 

 

303

 

 

 

289

 

Net loss allocated to common stockholders

$

(11,061

)

 

$

(13,808

)

 

$

(65,700

)

 

$

(39,627

)

 

 

 

 

 

 

 

 

Basic and diluted loss per share:

 

 

 

 

 

 

 

Common stock, basic and diluted

$

(0.05

)

 

$

(0.08

)

 

$

(0.30

)

 

$

(0.29

)

Series A Preferred Stock, basic and diluted

$

(0.05

)

 

$

(0.08

)

 

$

(0.30

)

 

$

(0.29

)

Weighted-average shares outstanding:

 

 

 

 

 

 

 

Common stock, basic

 

216,010,350

 

 

 

167,229,501

 

 

 

216,821,553

 

 

 

136,894,905

 

Common stock, diluted

 

217,010,350

 

 

 

168,229,501

 

 

 

217,821,553

 

 

 

137,894,905

 

Series A Preferred Stock, basic and diluted

 

1,000,000

 

 

 

1,000,000

 

 

 

1,000,000

 

 

 

1,000,000

 

TIC Solutions, Inc.

Condensed Consolidated Balance Sheets

(amounts in thousands)

(Unaudited)

 

 

September 30, 2026

 

December 31, 2025

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

197,908

 

$

439,536

Accounts receivable, net

 

471,348

 

 

366,293

Contract assets

 

212,592

 

 

154,439

Prepaid expenses and other current assets

 

65,268

 

 

60,768

Total current assets

 

947,116

 

 

1,021,036

Property and equipment, net

 

248,209

 

 

255,625

Operating lease right-of-use assets, net

 

56,866

 

 

60,209

Goodwill

 

1,756,474

 

 

1,649,595

Intangible assets, net

 

1,350,970

 

 

1,391,382

Deferred tax assets

 

1,396

 

 

1,438

Other assets

 

39,572

 

 

17,024

Total assets

$

4,400,603

 

$

4,396,309

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

82,575

 

$

60,426

Accrued expenses and other current liabilities

 

224,225

 

 

151,626

Contract liabilities

 

63,082

 

 

47,846

Current portion of long-term debt

 

23,118

 

 

25,511

Current portion of lease obligations

 

31,933

 

 

33,584

Total current liabilities

 

424,933

 

 

318,993

Long-term debt, net of current portion

 

1,586,478

 

 

1,587,686

Non-current lease obligations

 

64,937

 

 

66,049

Deferred tax liabilities

 

197,963

 

 

222,955

Other non-current liabilities

 

17,885

 

 

20,710

Total liabilities

 

2,292,196

 

 

2,216,393

Total stockholders’ equity

 

2,108,407

 

 

2,179,916

Total liabilities and stockholders’ equity

$

4,400,603

 

$

4,396,309

TIC Solutions, Inc.

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

(Unaudited)

 

 

Nine Months Ended

 

September 30, 2026

 

September 30, 2025

Cash flows from operating activities:

 

 

 

Net loss

$

(66,003

)

 

$

(39,916

)

Adjustments to reconcile net loss to cash flows from operating activities:

 

 

 

Depreciation and amortization

 

180,832

 

 

 

109,241

 

Noncash lease expense

 

18,526

 

 

 

10,002

 

Share-based compensation expense

 

35,483

 

 

 

9,271

 

Amortization of deferred financing costs

 

5,617

 

 

 

3,185

 

Deferred taxes

 

(36,735

)

 

 

(24,010

)

Other

 

2,713

 

 

 

2,678

 

Changes in operating assets and liabilities, net of effects of acquisitions:

 

 

 

Accounts receivable

 

(95,328

)

 

 

26,289

 

Contract assets

 

(66,122

)

 

 

(52,520

)

Prepaid expenses and other current assets

 

(1,444

)

 

 

1,450

 

Accounts payable

 

16,532

 

 

 

5,563

 

Accrued expenses and other current liabilities

 

61,341

 

 

 

5,489

 

Operating lease obligations

 

(18,237

)

 

 

(7,563

)

Contract liabilities

 

3,155

 

 

 

(2,736

)

Other assets and liabilities

 

(3,694

)

 

 

(1,093

)

Net cash provided by operating activities

 

36,636

 

 

 

45,330

 

 

 

 

 

Cash flows from investing activities:

 

 

 

Business acquisitions, net of cash acquired

 

(179,985

)

 

 

(838,399

)

Purchases of property and equipment

 

(39,531

)

 

 

(21,187

)

Proceeds from sale of property and equipment

 

3,115

 

 

 

3,141

 

Net cash used in investing activities

 

(216,401

)

 

 

(856,445

)

 

 

 

 

Cash flows from financing activities:

 

 

 

Proceeds from long-term borrowings

 

—

 

 

 

875,000

 

Payments on long-term borrowings

 

(8,211

)

 

 

(8,441

)

Payments of debt issuance costs

 

—

 

 

 

(24,331

)

Payments on finance lease obligations and other long-term debt

 

(24,380

)

 

 

(8,361

)

Payments related to tax withholdings for stock-based compensation

 

(2,965

)

 

 

—

 

Payments related to repurchases of common stock

 

(22,659

)

 

 

—

 

Net cash (used in) provided by financing activities

 

(58,215

)

 

 

833,867

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

(3,648

)

 

 

2,546

 

Net change in cash and cash equivalents

 

(241,628

)

 

 

25,298

 

 

 

 

 

Beginning of period

 

439,536

 

 

 

139,134

 

End of period

$

197,908

 

 

$

164,432

 

TIC Solutions, Inc.

Reconciliation of Non-GAAP Financial Measures

Adjusted Gross Profit and Adjusted Gross Margin

(amounts in thousands)

(Unaudited)

 

 

Three Months Ended September 30, 2026

 

Inspection &

Mitigation

 

Consulting &

Engineering

 

Geospatial

 

Total

Revenue

$

318,172

 

 

$

223,178

 

 

$

98,270

 

 

$

639,620

 

Cost of revenue

 

239,359

 

 

 

117,337

 

 

 

56,595

 

 

 

413,291

 

Gross profit

$

78,813

 

 

$

105,841

 

 

$

41,675

 

 

$

226,329

 

Depreciation expense included in cost of revenue

 

14,238

 

 

 

—

 

 

 

2,420

 

 

 

16,658

 

Adjusted gross profit

$

93,051

 

 

$

105,841

 

 

$

44,095

 

 

$

242,987

 

Adjusted gross margin(1)

 

29.2

%

 

 

47.4

%

 

 

44.9

%

 

 

38.0

%

 

Three Months Ended September 30, 2025

 

Inspection &

Mitigation

 

Consulting &

Engineering

 

Geospatial

 

Total

Revenue

$

293,187

 

 

$

119,583

 

 

$

61,118

 

 

$

473,888

 

Cost of revenue

 

226,268

 

 

 

61,746

 

 

 

33,147

 

 

 

321,161

 

Gross profit

$

66,919

 

 

$

57,837

 

 

$

27,971

 

 

$

152,727

 

Depreciation expense included in cost of revenue

 

16,446

 

 

 

—

 

 

 

1,757

 

 

 

18,203

 

Adjusted gross profit

$

83,365

 

 

$

57,837

 

 

$

29,728

 

 

$

170,930

 

Adjusted gross margin(1)

 

28.4

%

 

 

48.4

%

 

 

48.6

%

 

 

36.1

%

 

Combined Three Months Ended September 30, 2025

 

Inspection &

Mitigation

 

Consulting &

Engineering(2)

 

Geospatial(2)

 

Total

Revenue

$

293,187

 

 

$

185,527

 

 

$

89,934

 

 

$

568,648

 

Cost of revenue

 

226,268

 

 

 

97,493

 

 

 

49,049

 

 

 

372,810

 

Gross profit

$

66,919

 

 

$

88,034

 

 

$

40,885

 

 

$

195,838

 

Depreciation expense included in cost of revenue

 

16,446

 

 

 

—

 

 

 

2,430

 

 

 

18,876

 

Adjusted gross profit

$

83,365

 

 

$

88,034

 

 

$

43,315

 

 

$

214,714

 

Adjusted gross margin(1)

 

28.4

%

 

 

47.5

%

 

 

48.2

%

 

 

37.8

%

(1)

Adjusted Gross Margin is calculated as Adjusted Gross Profit divided by revenue for the applicable period.

(2)

The amounts presented for the combined three months ended September 30, 2025 for Consulting & Engineering and Geospatial are based on the Company’s reclassification of certain costs that NV5 historically presented within “Salaries and wages, payroll taxes, and benefits” which the Company classifies as “Cost of revenue.”

TIC Solutions, Inc.

Reconciliation of Non-GAAP Financial Measures

Adjusted Gross Profit and Adjusted Gross Margin

(amounts in thousands)

(Unaudited)

 

 

Nine Months Ended September 30, 2026

 

Inspection &

Mitigation

 

Consulting &

Engineering

 

Geospatial

 

Total

Revenue

$

849,694

 

 

$

617,189

 

 

$

245,112

 

 

$

1,711,995

 

Cost of revenue

 

662,872

 

 

 

324,569

 

 

 

132,766

 

 

 

1,120,207

 

Gross profit

$

186,822

 

 

$

292,620

 

 

$

112,346

 

 

$

591,788

 

Depreciation expense included in cost of revenue

 

47,635

 

 

 

—

 

 

 

7,057

 

 

 

54,692

 

Adjusted gross profit

$

234,457

 

 

$

292,620

 

 

$

119,403

 

 

$

646,480

 

Adjusted gross margin(1)

 

27.6

%

 

 

47.4

%

 

 

48.7

%

 

 

37.8

%

 

Nine Months Ended September 30, 2025

 

Inspection &

Mitigation

 

Consulting &

Engineering

 

Geospatial

 

Total

Revenue

$

841,327

 

 

$

119,583

 

 

$

61,118

 

 

$

1,022,028

 

Cost of revenue

 

656,638

 

 

 

61,746

 

 

 

33,147

 

 

 

751,531

 

Gross profit

$

184,689

 

 

$

57,837

 

 

$

27,971

 

 

$

270,497

 

Depreciation expense included in cost of revenue

 

48,028

 

 

 

—

 

 

 

1,757

 

 

 

49,785

 

Adjusted gross profit

$

232,717

 

 

$

57,837

 

 

$

29,728

 

 

$

320,282

 

Adjusted gross margin(1)

 

27.7

%

 

 

48.4

%

 

 

48.6

%

 

 

31.3

%

 

Combined Nine Months Ended September 30, 2025

 

Inspection &

Mitigation

 

Consulting &

Engineering (2)

 

Geospatial (2)

 

Total

Revenue

$

841,327

 

 

$

533,436

 

 

$

228,054

 

 

$

1,602,817

 

Cost of revenue

 

656,638

 

 

 

282,800

 

 

 

120,745

 

 

 

1,060,183

 

Gross profit

$

184,689

 

 

$

250,636

 

 

$

107,309

 

 

$

542,634

 

Depreciation expense included in cost of revenue

 

48,028

 

 

 

—

 

 

 

6,096

 

 

 

54,124

 

Adjusted gross profit

$

232,717

 

 

$

250,636

 

 

$

113,405

 

 

$

596,758

 

Adjusted gross margin(1)

 

27.7

%

 

 

47.0

%

 

 

49.7

%

 

 

37.2

%

(1)

Adjusted Gross Margin is calculated as Adjusted Gross Profit divided by revenue for the applicable period.

(2)

The amounts presented for the combined nine months ended September 30, 2025 for Consulting & Engineering and Geospatial are based on the Company’s reclassification of certain costs that NV5 historically presented within “Salaries and wages, payroll taxes, and benefits” which the Company classifies as “Cost of revenue.”

TIC Solutions, Inc.

Reconciliation of Non-GAAP Financial Measures

Adjusted EBITDA and Adjusted EBITDA Margin

(amounts in thousands)

(Unaudited)

 

 

Three Months Ended

 

Nine Months Ended

 

September 30, 2026

 

September 30, 2025

 

September 30, 2026

 

September 30, 2025

Net loss

$

(11,112

)

 

$

(13,890

)

 

$

(66,003

)

 

$

(39,916

)

Income tax benefit

 

(1,149

)

 

 

(16,559

)

 

 

(20,842

)

 

 

(11,184

)

Interest expense, net

 

29,251

 

 

 

26,521

 

 

 

86,637

 

 

 

57,979

 

Depreciation and amortization expense

 

61,529

 

 

 

51,128

 

 

 

180,832

 

 

 

109,241

 

EBITDA

 

78,519

 

 

 

47,200

 

 

 

180,624

 

 

 

116,120

 

Adjustments:

 

 

 

 

 

 

 

Share-based compensation expense(1)

 

11,245

 

 

 

6,291

 

 

 

35,483

 

 

 

9,271

 

ASP Acuren Acquisition transaction related expenses(2)

 

—

 

 

 

—

 

 

 

—

 

 

 

467

 

Acquisition related transaction and integration expenses(3)

 

15,984

 

 

 

23,932

 

 

 

38,793

 

 

 

26,674

 

Business transformation costs(4)

 

802

 

 

 

1,462

 

 

 

4,350

 

 

 

6,082

 

Other non-recurring charges(5)

 

698

 

 

 

(1,571

)

 

 

593

 

 

 

(908

)

Adjusted EBITDA

$

107,248

 

 

$

77,314

 

 

$

259,843

 

 

$

157,706

 

Revenue

 

639,620

 

 

 

473,888

 

 

 

1,711,995

 

 

 

1,022,028

 

Adjusted EBITDA margin(6)

 

16.8

%

 

 

16.3

%

 

 

15.2

%

 

 

15.4

%

(1)

Adjustment to add back share-based compensation expense.

(2)

Adjustment to add back transaction related expenses for the Acuren Acquisition.

(3)

Adjustment to add back transaction and acquisition integration related costs and similar items for acquisitions not including the Acuren Acquisition. This includes costs related to the NV5 Acquisition.

(4)

Adjustment to reflect the elimination of non-recurring costs related to business transformation expenses.

(5)

Adjustment to add back other non-recurring charges.

(6)

Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by revenue for the applicable period.

TIC Solutions, Inc.

Non-GAAP Financial Measure

Organic Change in Revenue (On an NV5 Combined Basis)

(Unaudited)

 

 

Three Months Ended

September 30, 2026

 

Nine Months Ended

September 30, 2026

Change in Revenue (As Reported)

35.0

%

 

67.5

%

Impact from NV5 Revenue(1)

22.5

%

 

60.7

%

Total Combined Revenue Growth

12.5

%

 

6.8

%

Foreign Currency Translation(2)

0.5

%

 

(0.3

)%

Total Combined Revenue Growth (Constant Currency)

13.0

%

 

6.5

%

Acquisitions(3)

(4.6

)%

 

(2.2

)%

Organic Change in Revenue (NV5 Combined)

8.4

%

 

4.3

%

(1)

Adjusted for NV5’s revenue prior to August 4, 2025 in the three and nine months ended September 30, 2025 for purposes of calculating combined organic revenue growth.

(2)

Represents the effect of foreign currency on reported revenue, calculated as the difference between reported revenue and revenue at fixed currencies for the period. Fixed currency amounts are based on translation into U.S. Dollars at fixed foreign currency exchange rates established by management.

(3)

Adjustment to exclude revenue from acquisitions, other than di minimis acquisitions, from their respective dates of acquisition until the first-year anniversary from date of acquisition. This adjustment also excludes material NV5 acquisitions from the combined comparable period.

TIC Solutions, Inc.

Reconciliation of Non-GAAP Financial Measure

Adjusted SG&A Expenses

(amounts in thousands)

(Unaudited)

 

 

Three Months Ended

 

Nine Months Ended

 

September 30, 2026

 

September 30, 2025

 

September 30, 2026

 

September 30, 2025

Selling, general and administrative expenses (“SG&A”)

$

210,337

 

 

$

159,240

 

 

$

594,016

 

 

$

268,099

 

Adjustments:

 

 

 

 

 

 

 

Depreciation and amortization

 

(44,871

)

 

 

(32,925

)

 

 

(126,140

)

 

 

(59,457

)

Share-based compensation expense(1)

 

(11,245

)

 

 

(6,291

)

 

 

(35,483

)

 

 

(9,271

)

Acuren Acquisition transaction related expenses(2)

 

—

 

 

 

—

 

 

 

—

 

 

 

(467

)

Acquisition related transaction and integration expenses(3)

 

(15,984

)

 

 

(25,111

)

 

 

(36,729

)

 

 

(27,877

)

Business transformation costs(4)

 

(802

)

 

 

(2,011

)

 

 

(4,350

)

 

 

(6,592

)

Other non-recurring charges(5)

 

(1,056

)

 

 

447

 

 

 

(2,515

)

 

 

(723

)

Adjusted SG&A expenses

$

136,379

 

 

$

93,349

 

 

$

388,799

 

 

$

163,712

 

Revenue

 

639,620

 

 

 

473,888

 

 

 

1,711,995

 

 

 

1,022,028

 

Adjusted SG&A expenses as a % of revenue

 

21.3

%

 

 

19.7

%

 

 

22.7

%

 

 

16.0

%

(1)

Adjustment to add back share-based compensation expense.

(2)

Adjustment to add back transaction related expenses for the Acuren Acquisition.

(3)

Adjustment to add back transaction and acquisition integration related costs and similar items for acquisitions not including the Acuren Acquisition. This includes costs related to the NV5 Acquisition.

(4)

Adjustment to reflect the elimination of non-recurring costs related to business transformation expenses.

(5)

Adjustment to add back other non-recurring charges.

TIC Solutions, Inc.

Reconciliation of Non-GAAP Financial Measure

Adjusted EPS

(amounts in thousands except share and per share data)

(Unaudited)

 

 

Three Months Ended

 

Nine Months Ended

 

September 30, 2026

 

September 30, 2026

Net loss (as reported)

$

(11,112

)

 

$

(66,003

)

Adjustments:

 

 

 

Amortization of intangible assets

 

40,306

 

 

 

114,445

 

Share-based compensation expense

 

11,245

 

 

 

35,483

 

Acquisition related transaction and integration expenses

 

15,984

 

 

 

38,793

 

Business transformation costs

 

802

 

 

 

4,350

 

Other non-recurring charges

 

698

 

 

 

593

 

Income tax provision adjustment(1)

 

(17,259

)

 

 

(48,416

)

Adjusted net income

$

40,664

 

 

$

79,245

 

Income allocated to Series A Preferred Stock

 

(187

)

 

 

(365

)

Adjusted net income allocated to common stockholders

$

40,477

 

 

$

78,880

 

 

 

 

 

Common stock, diluted (as reported)

 

217,010,350

 

 

 

217,821,553

 

Adjustments:

 

 

 

Dilutive impact of restricted stock awards(2)

 

2,646,664

 

 

 

3,049,327

 

Dilutive impact of restricted stock units(2)

 

1,569,952

 

 

 

1,121,208

 

Adjusted common stock, diluted

 

221,226,966

 

 

 

221,992,088

 

 

 

 

 

Adjusted EPS, diluted

$

0.18

 

 

$

0.36

 

(1)

Adjustment represents the income tax effect of the pre-tax adjustments using an estimated adjusted effective tax rate of 25.0%.

(2)

Adjustment reflects the addition of the dilutive impact of restricted stock awards and restricted stock units.

 

Investor Relations Contacts

Andrew Shen

Vice President of Investor Relations

Email: [email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Oil/Gas Energy Technology Other Construction & Property White House/Federal Government State/Local Commercial Building & Real Estate Construction & Property Engineering Urban Planning Other Technology Public Policy/Government Manufacturing

MEDIA:

Logo
Logo

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing

Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN; initial data expected in the first half of 2027

Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027

Initial budoprutug Phase 1b data in SLE demonstrated a favorable safety and tolerability profile and dose-dependent B-cell depletion; additional Phase 1b data in ITP at American Society of Hematology in December 2026

$227.6 million in cash, cash equivalents and marketable securities as of September 30, 2026; expected cash runway into the second half of 2028

WELLESLEY HILLS, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

“We are building significant momentum across our programs, CLYM116 and budoprutug” said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. “For CLYM116, two independent datasets support a best-in-class anti-APRIL profile and initial budoprutug data from our ongoing Phase 2 PrisMN study in primary membranous nephropathy demonstrated meaningful B-cell depletion and immunologic remission at 200 mg, with potential for increased activity at higher doses. We are also pleased with the initial data from our ongoing global study of budoprutug in SLE, which showed that budoprutug was generally well tolerated, with no serious adverse events, and that a single dose of 10-100 mg produced dose-dependent B-cell depletion and SLEDAI-2K reductions. We’ve reported data across both programs throughout 2026, and we look forward to closing out a data-rich year with additional ITP data at ASH in December. Looking ahead, we are poised to enter 2027 with two promising programs, multiple anticipated data readouts across both, and the potential to initiate pivotal studies.”

CLYM116 Program Updates and Anticipated Milestones

  • Initiated dosing in NAVIGATE-2 Phase 2 trial in IgA nephropathy (IgAN); enrollment ongoing. NAVIGATE-2 is a randomized, open-label study evaluating an 800 mg loading dose of CLYM116 followed by 400 mg every 8 weeks (Q8W) or every 12 weeks (Q12W), intended to support advancement of a Q12W regimen into Phase 3. Anticipate initial NAVIGATE-2 data in the first half of 2027, and initiation of a global Phase 3 trial in 2027, pending regulatory feedback.
  • Reported encouraging Phase 1 data supporting Q12W dosing interval at the September R&D Spotlight Event and American Society of Nephrology (ASN) Kidney Week 2026. CLYM116 was evaluated in complementary Phase 1 trials in Australia and China, both randomized, double-blind, placebo-controlled, ascending-dose studies designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) CLYM116 in healthy volunteers and enrolled 46 and 42 participants, respectively. Across both studies, PK was linear, with no target-mediated drug disposition (TMDD) observed across the effective dose range, and >90% free APRIL suppression was sustained through 12 weeks following a single SC dose of ≥480 mg. Following a single 800 mg dose, ~70% reduction in Gd-IgA1 and ~60% reduction in IgA were observed at 12 weeks. Together, these PK and PD data support a Q12W dosing regimen. CLYM116 has been generally well tolerated, with no dose-limiting toxicities, treatment-related serious adverse events (SAEs), or hypogammaglobulinemia.

Budoprutug Program Updates and Anticipated Milestones

  • Presented initial data from the PrisMN Phase 2 primary membranous nephropathy (pMN) trial in an oral presentation at ASN Kidney Week 2026; enrollment ongoing. PrisMN is a global open-label, dose-escalation Phase 2 study designed to evaluate safety, PK, PD (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria despite optimized renin-angiotensin-aldosterone system (RAAS) inhibition, and to identify a dose for Phase 3 clinical development. Patients enrolled in the reported cohorts were treatment-experienced, with high proteinuria and elevated PLA2R antibody levels at baseline. At Week 12, the 200 mg cohort demonstrated B-cell depletion, reductions in PLA2R antibody levels, and immunologic remission. Phase 2 Week 12 data in the 200 mg cohort were consistent with Phase 1b Week 12 data. Initial data from the ongoing 600 mg cohort suggest greater drug exposure and deeper peripheral B-cell depletion compared with 200 mg. Budoprutug has been generally well tolerated in both cohorts to date, with follow-up through Week 12 for 200 mg and Week 6 for 600 mg. Enrollment is ongoing in the third cohort (1000 mg), additional data from all cohorts, including longer-term follow-up, expected in 2027.
  • Presented minimal change disease (MCD) case study at ASN Kidney Week 2026. A poster described a durable response following budoprutug treatment in a patient with MCD, highlighting the potential role of CD19-targeted B-cell depletion in podocytopathies beyond pMN.
  • Initial data from the ongoing global Phase 1b trial in systemic lupus erythematosus (SLE), demonstrated dose-dependent B-cell depletion and reductions in disease activity. The global, open-label, dose-escalation Phase 1b trial of budoprutug in moderate to severe SLE is designed to evaluate safety, tolerability, PK, PD, and preliminary efficacy, including B-cell depletion, autoantibody levels, and clinical activity. As of the October 7, 2026 data cutoff, 17 participants had enrolled across the 10 mg, 30 mg and 100 mg single-dose cohorts. B-cell depletion deepened and was more durable with increasing dose, reaching a mean reduction of 84% at Week 12 in the 100 mg cohort. Reductions of ≥4 points in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores were observed at Week 12 in seven of 12 participants in the 30 mg and 100 mg cohorts, compared with none of the five participants in the 10 mg cohort. Budoprutug was generally well tolerated, with no SAEs, discontinuations due to adverse events, or infusion-related reactions reported. Enrollment is ongoing in the final 200 mg cohort and dosing continues in a parallel Phase 1b/2a trial in China. Anticipate additional data from both ongoing studies in 2027.
  • Additional data from the ongoing Phase 1b trial in immune thrombocytopenia (ITP) to be presented at the American Society of Hematology (ASH) Annual Meeting. This global open-label, dose-escalation Phase 1b trial of budoprutug in previously treated patients with ITP is designed to evaluate safety, tolerability, PK, PD, and preliminary efficacy, including B-cell depletion and platelet counts. Initial Phase 1b data in ITP were presented at the European Hematology Association Congress in June 2026. Additional data from the 500 mg and 1000 mg cohorts to be presented at ASH in December 2026.
  • Plans to initiate study of the SC formulation of budoprutug in autoimmune disease patients. Following positive single-dose data for the SC formulation in May 2026, the Company plans to initiate SC study in autoimmune disease patients. Anticipate initial SC data in 2027.

Third Quarter Financial Results and Guidance

  • Cash Position: Cash, cash equivalents, and marketable securities were $227.6 million as of September 30, 2026. Based on its current operating plan, the Company expects this balance to fund operations into the second half of 2028.
  • Research and Development (R&D) Expenses: R&D expenses were $11.0 million for the three months ended September 30, 2026, compared to $9.1 million for the comparable period in 2025.
  • General and Administrative (G&A) Expenses: G&A expenses were consistent at $5.8 million for both the three months ended September 30, 2026 and 2025.
  • Other Income, Net: Other income, net was $2.3 million for the three months ended September 30, 2026, compared to $2.0 million for the comparable period in 2025.

About Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com. 

About CLYM116

CLYM116 is a clinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of plasma cell survival and pathogenic IgA production in autoimmune diseases. CLYM116 employs an engineered pH-dependent bind-and-release ‘sweeper’ mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for deep and durable inhibition of APRIL with a favorable safety profile and less frequent dosing. In a Phase 1 study in healthy volunteers, CLYM116 demonstrated near-complete APRIL suppression through 12 weeks, supporting the potential for Q12W dosing. CLYM116 is being advanced for the treatment of IgA nephropathy (IgAN) and has potential utility across other B-cell mediated diseases where APRIL plays a critical role.

About Budoprutug

Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.

Forward-Looking Statements

This press release contains “forward-looking statements,” including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; the anticipated timelines for announcing data from and enrolling patients in Climb Bio’s ongoing and planned clinical trials; the anticipated timing of initiation of a Phase 3 trial of CLYM116; expectations regarding cash runway; projections and estimates derived from pharmacokinetic and pharmacodynamic modeling; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “expect,” “may,” “plan,” “potential,” “should,” “suggest,” “target,” “will,” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co. Ltd.; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulations; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law. 

Investors and Media

Carlo Tanzi, Ph.D.
Kendall Investor Relations
[email protected]

Climb Bio, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(unaudited)
           
    30-Sep-26     31-Dec-25
Assets          
Cash, cash equivalents and marketable securities   $ 227,625     $ 160,652
Other assets     8,939       7,092
Total assets   $ 236,564     $ 167,744
Liabilities and stockholders’ equity          
Liabilities   $ 8,511     $ 7,269
Total stockholders’ equity     228,053       160,475
Total liabilities and stockholders’ equity   $ 236,564     $ 167,744
               

Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(unaudited)
                                 
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Operating expenses:                        
Research and development   $ 11,044     $ 9,073     $ 30,131     $ 32,975  
General and administrative     5,849       5,819       17,332       15,612  
Total operating expenses     16,893       14,892       47,463       48,587  
Loss from operations     (16,893 )     (14,892 )     (47,463 )     (48,587 )
Other income, net     2,320       2,004       5,670       6,252  
Net loss   $ (14,573 )   $ (12,888 )   $ (41,793 )   $ (42,335 )
Net loss per share, basic and diluted   $ (0.18 )   $ (0.19 )   $ (0.56 )   $ (0.63 )
                                 



iMDx to Release Third Quarter Results on November 16, 2026

NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the market closes on Monday, November 16, 2026. iMDx will host a live Zoom webinar to discuss the company’s financial results at 2:00 pm PT / 5:00 pm ET that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q3 2026 Earnings Webinar.

An archived replay will be available after the call concludes on iMDx’s website within the Investors/Events & Presentations section.

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact:

Alexandra Grossman
LifeSci Advisors LLC
[email protected]